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2. Abstract 
 
Il tumore al pancreas è un cancro che origina dalle cellule 
all’interno della ghiandola addominale chiamata pancreas. La 
prognosi è considerata generalmente grave a causa della diagnosi 
spesso tardiva. Il cancro al pancreas non presenta all’inizio chiari 
sintomi ed e’ caratterizzato da una rapida disseminazione 
metastatica e resistenza alla chemioterapia. Recentemente queste 
due caratteristiche sono state descritte come conseguenza di un 
processo di transizione epitelio-mesenchimale (EMT) delle cellule 
tumorali. 
In questo studio abbiamo cercato di chiarire il ruolo della 
proteina di membrana caveolina-1 (CAV-1) in EMT. Caveolina-1  è 
la molecola principale costituente delle caveolae, invaginazioni 
ricche di sfingolipidi e colesterolo della membrana plasmatica. E’ 
stato riportato che Cav-1 è implicata nella regolazione 
dell’espressione della proteina E-caderina e nel processo EMT. Noi 
abbiamo infettato una linea cellulare umana tumorale pancreatica, 
Panc 10.05, con il vettore retrovirale pBABE con inserito o meno il 
c-DNA della caveolina-1. Il risultato e’ stato che le cellule 
Panc10/cav-1 presentavano una morfologia poligonale ed erano 
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più aderenti tra loro rispetto alle cellule trasfettate con il vettore 
vuoto (Panc10/pBabe) che mostravano una morfologia fusiforme e 
allungata e meno contatto tra le cellule. Inoltre, l'analisi con 
immunofluorescenza e western blot ha dimostrato che nelle cellule 
Panc10/cav-1 era ripristinata l’espressione della proteine E-
caderina e  β-catenina a livello della membrana plasmatica. La 
perdita dell’espressione di E-caderina è considerata un marker del 
processo di EMT e il suo recupero è una prova convincente 
dell’inibizione di EMT. Per approfondire il nostro studio abbiamo 
analizzato l’espressione di proteine regolatrici  della E-caderina.  
Uno degli inibitori, Snail, è risultato essere down-regolato nelle 
cellule Panc10/cav-1. Abbiamo anche mostrato che l’espressione 
della cav-1 attenuava l'attivazione di numerose molecole coinvolte 
in EMT, come ERK, Smad2 e AKT. La disattivazione di queste 
molecole si traduceva nella diminuzione della migrazione e 
invasione delle cellule tumorali oltre a diminuire la resistenza alla 
chemioterapia. Panc10/cav-1 coltivate su matrigel, sistema di 
coltura tridimensionale, ha mostrato la formazione di sfere regolari, 
poche ramificazione e irregolarità che sono un'indicazione di EMT e 
invasività. Inoltre abbiamo mostrato che la linea cellulare tumorale 
pancreatica altamente metastatica, ASPC-1, quando incubata con il 
peptide di CAV-1, produceva un significativo arresto del ciclo 
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cellulare. Infine, abbiamo iniettato le cellule Panc10 nel fianco di 
topi nudi, cosiddetti perche’ atimici e quindi immunodepressi. I 
tumori ottenuti dall’iniezione di Panc10 /cav-1 erano più piccoli in 
peso e in volume rispetto ai tumori ottenuti con le cellule 
Panc10/pBabe. Sorprendentemente i tumori Panc10/cav-1 
presentavano agglomerati di cellule differenziate e ben organizzate 
che erano assenti nei tumori Panc10/pBabe. Queste cellule 
differenziate esprimevano E-caderina e β-catenina a livello della 
membrana cellulare oltre ad esprimere a basso livello la proteina 
Snail.  
In conclusione questi risultati suggeriscono che la cav-1 agisce 
come inibitore del processo EMT nelle cellule tumorali pancreatiche 
attraverso il ripristino della proteina E-caderina e l'inibizione di 
molecole regolatrici di EMT. CAV-1 puo’ rappresentare 
potenzialmente una cura per la malattia del cancro al pancreas.  
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Pancreatic cancer is considered to be one of the deadliest 
cancers due to its rapid metastasis and high chemoresistance. 
Recently, these two characteristics were identified to be a 
consequence of  epithelial to mesenchymal transition (EMT). We 
wanted in this study to elucidate caveolin-1 (cav-1) role in EMT. 
Caveolin-1 (cav-1) is the main constituent molecule of caveolae, 
which are omega (Ω)-shaped invaginations found in plasma 
membrane. Cav-1 has been found to be implicated in regulation of 
E-cadherin and EMT, however little is known about the regulation 
mechanism.  In this study, we infected pancreatic cancer cell line, 
Panc 10.05, with cav-1 expressing vector (Panc10/cav-1). 
Consequently to cav-1 infection, Panc10/cav-1 cell line displayed 
polygonal morphology and more cell adherens compared to Panc 
10.05 infected with empty vector (Panc10/pBabe), which displayed 
spindle-shape morphology and less cell-cell contact. Also, our 
immunoblotting and immunofluorescence analysis showed that 
Panc10/cav-1 restored E-cadherin and β-catenin expression in the 
plasma membrane. E-cadherin loss is conceded as the hallmark of 
EMT, and its restoration is a convincing evidence of EMT inhibition. 
To study how cav-1 restored E-cadherin expression, we performed 
immunoblotting analysis for E-cadherin expression regulators. Snail 
,is one of E-cadherin inhibitors, was found to be down-regulated in 
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Panc10/cav-1. Also, we found that cav-1 attenuated the activity of 
several molecules in EMT pathway such ERK, Smad2 and AKT in 
Panc10/cav-1 cells. This attenuation of EMT molecules activity was 
accompanied by decrease in migration, invasion and 
chemoresistance. Also, Panc10/cav-1 grown on three-dimensional 
culture showed regular spheres, and less branching and irregularity 
which are an indication of EMT and invasiveness. Furthermore, we 
showed that the metastatic pancreatic cancer cell line, Aspc-1, 
when incubated with cav-1 peptide, displayed significant cell cycle 
arrest. Finally, we injected infected cell in nude mice flank. 
Panc10/cav-1 tumors were smaller in weight and volume compared 
to Panc10/pBabe tumors. Astonishingly, Panc10/cav-1 tumors 
displayed nests of differentiated arranged cells surrounded by poor 
differentiated cells which were absent in Panc10/pBabe tumors. 
These differentiated cells expressed E-cadherin and β-catenin in 
the cell membrane, and down-regulated Snail expression.  
In summary, these results provide evidence that cav-1 act as 
an EMT inhibitor in pancreatic cancer cells, through restoration of 
E-cadherin expression and inhibition of EMT initiator molecules. 
Also, cav-1 appears to be an important regulator of invasion, 
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chemoresistance, tumor proliferation and cell differentiation which 
presents cav-1 as a potential cure for pancreatic cancer disease. 
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3. Introduction 
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3.1 Pancreatic Cancer 
3.1.1 Epidemiology 
Pancreatic ductal adenocarcinoma (PDA) is the fourth most 
common cause of cancer-related death and its incidence is 
estimated to be around 9 patients per 100,000 individuals (Jemal et 
al., 2009). With a five-year survival rate of only 3% and a median 
survival of less than 6 months, a diagnosis of pancreatic cancer 
carries one of the most dismal prognoses in all of medicine. 
Patients in their 70’s or 80’s experience unexplained weight lose, 
back pain , altered bowel syndrome habit, or sudden onset of 
jaundice. During clinical evaluation, a mass is found  in the 
pancreas, usually the head of the pancreas, the right sided-region 
of pancreas adjacent to the duodenum. Due to the late diagnosis of 
the disease, in 80% of the patients is clinically evident that the 
cancer has already spread to other organs, most commonly to the 
liver (Kern, Hruban, Hidalgo, & Yeo, 2002). The other 20% of 
patients who have no detectable metastatic disease are candidates 
for surgical resection. Patients with resected pancreatic tumor have 
between 15-20% to live five-year (Sohn et al., 2000). Even if 
surgical resection is performed, unfortunately, all pancreatic cancer 
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patients succumb to metastatic disease (Yachida & Iacobuzio-
Donahue, 2009). 
 
3.1.2 Risk Factors 
Due to incurability of pancreatic cancer patients, many 
researchers have inspected disease prevention and risk factors 
identification and involvement in development of PDA. A number of 
risk factors have been identified (Lowenfels & Maisonneuve, 2006). 
PDA is considered as a disease of elderly people. Pancreatic 
cancer is infrequent before the age 40, and the median age at 
diagnosis is 73 years (http://seer.cancer.gov/). Also, the 
Surveillance, Epidemiology and End Results (SEER) based on the 
U.S population shows that black African population has higher risk 
of development of PDA more than white population. Silverman et al 
showed that this higher incidence of PDA in black African is due to 
environmental factors like elevated body mass index and higher 
alcohol consumption and when these factors are absent, incident 
rate of PDA in black African probably will not exceed incident rate 
of white Americans (Silverman et al., 2003). On the contrary, 
Pernick et al assumed that genetic mutations and biomarkers  
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differences between the two races are the explanation of higher 
incidence rate in black African more than white cucasians (Pernick 
et al., 2003). 
 
As smoking cigarettes is the most documented etiologic 
factor, PDA can be preventable by stopping this habit(Stolzenberg-
Solomon et al., 2001; Villeneuve, Johnson, Hanley, & Mao, 2000) 
.Cigarettes smoking nearly doubles the risk of PDA, and it is 
believed that as one in four cases of PDA may be attributable to 
smoking (Lowenfels & Maisonneuve, 2006). Other established risk 
factor include high fat and meat diets, low serum folate levels, 
obesity, diabetes mellitus, and chronic pancreatitis (Everhart & 
Wright, 1995; Lowenfels & Maisonneuve, 2006; Michaud et al., 
2001; Michaud et al., 2002). As coffee was accused to be one of 
the risk factors of the PDA, more recent studies do not show any 
significant association (Lowenfels & Maisonneuve, 2006). 
 
One of the interesting risk factor of PDA is family pancreatic 
cancer history. It is considered to  cause pancreas cancer in less 
than 10% of all PDA cases(Bardeesy & DePinho, 2002; Maitra & 
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Hruban, 2008). Amundadottir et al analyzed 32,534 cancer cases 
diagnosed in Iceland from 1 January 1955 till December 31 2002. 
They evaluated any significance of the familial clustering for each 
relationship separately, all relationships combined (first- to fifth-
degree relatives) and for close (first- and second-degree) and 
distant (third- to fifth-degree) relatives. They found that pancreas 
cancer is increased by 2.3-fold for first-degree relative, and folds 
decreases with the distance of the relative until it reaches 0.9-fold 
in fifth-degree relative (Amundadottir et al., 2004). Also, Klein et al. 
have demonstrated that individuals with a strong family history of 
PDA have a significantly increased risk of developing pancreatic 
cancer (Klein et al., 2004).  Table 1 summarizes some of germ-line 
alteration which can be associated to risk pancreas cancer (Bartsch 
et al., 2002; de vos tot Nederveen Cappel et al., 2003; Giardiello et 
al., 2000; Goggins et al., 1998; Goggins et al., 1996; Lowenfels et 
al., 1997; Lynch et al., 2005; Ozcelik et al., 1997; Petersen et al., 
2006; Su et al., 1999).  
 
Maitra et al had revealed six characteristic of the genetic 
syndromes associated with the familial clustering of PDA (Maitra & 
Hruban, 2008). Firstly, they mentioned that cancer is not inevitable 
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in mutation gene carries. This appears in Goggins et al study which 
they screened  41 adenocarcinoma of pancreas (30 pancreatic 
adenocarcinoma xenografts and 11 PDA cell lines) and four (9.8%) 
of the 41 patients harbored a germ-line BRCA2 gene mutation 
(Goggins et al., 1996). One of the four mutation cases had a breast 
cancer-relative. Obviously, strong family history of cancer can be 
used for better screening of gene mutation carriers.  
 
Secondly, patients identified with these gene mutations, 
should be screened and advised that they may acquire a PDA in 
the future. For example, Peutz-Jeghers syndrome is characterized 
by hamartomatous gastrointestinal polyps and mucocutaneous 
pigmentation, and melanocytic macules on the lips and buccal 
mucosa (Giardiello et al., 2000). Patients with these syndrome 
should be tested for STK11/LKB1  mutation. Those who carry this 
mutation will be screened for asymptomatic PDA (Canto et al., 
2006). 
 
Thirdly, most of pancreatic gene mutations are associated 
with developing other cancers, too. For instance, p16/CDKN2A 
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mutation carriers have a risk of developing melanoma that can 
reach 28% at the age of 80 (Begg et al., 2005) . 
 
Fourthly, PDA with microsatellite instability often shows a 
distinct medullary histology. These medullary carcinoma hallmarked 
with DNA mismatch repair defects in MHL1/MSH2 genes and 
demonstrates poor cell boundaries and syncytial growth pattern of 
the cells (Wilentz, Goggins et al., 2000). PDA patients exhibit this 
morphologic appearance may benefit from genetic counseling. 
 
Fifthly, different therapeutic regimes can be selected 
according to patients’ genetic mutations. For example, the protein 
product of BRCA2 gene binds with the protein products of the 
Fanconi anemia complementation genes (the FANC genes) to form 
a homologues recombination. Van der Heijden et al have 
demonstrated that PDA with  BRCA2  or other proximal FANC gene 
mutations are particularly sensitive to Mitomycin C and radiation 
therapies which produce DNA cross-linking then breaks in double 
strands (van der Heijden et al., 2004).  
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Lastly, some ethnic groups can carry some of these genetic 
mutations. This is implied in the Ashkenazi Jewish population that 
1% of it carried the 6174delT BRCA2 gene mutation (Ozcelik et al., 
1997). 
 
3.1.3 Pathology 
Pancreatic cancer or pancreatic ductal adenocarcinoma 
(PDA) are tumors arising from pancreatic exocrine ductal cells. 
70% of PDA originates from the head of the pancreas and the rest 
arises from the body and the tail of the pancreas. Other tumors 
arise from tissues surrounding pancreas like ampullary 
adenocarcinoma which arises from the ampulla of Vater, pre-
ampullary adenocarcinoma which  describes tumors near the 
Ampulla of Vater, distal cholangiocarcinoma which arises from the 
distal bile duct adjacent to the Ampulla and duodenal 
adenocarcinoma which arises from the duodenum adjacent to the 
Ampulla. There are other tumors arise from pancreas like 
neuroendocrine tumors. My thesis will focus only on PDA 
pathology. 
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Since there are few millimeters of separation between these 
tumors, it is essential to differentiate between them as they vary 
greatly of their prognosis. Yeo et al observed at 242 patients that 
underwent pancreaticoduodenal resection for periampullary 
adenocarcinoma over 22 years (Yeo et al., 1998). Of the 242 
patients with resected periampullary adenocarcinoma, 149 (62%) 
were PDA, 46 (19%) were ampullary adenocarcinomas, 30 (12%) 
were cholangiocarcinomas, and 17 (7%) were duodenal cancers. 
The post-operative 5 year survival percent was lowest in PDA 
(15%), then ampullary adenocarcinoma (25%), 
cholangiocarcinomas (27%) and duodenal adenocarcinoma (59%). 
In this study, Yeo et al displayed differences between PDA and non 
PDA patients’ outcome. Also, they indicated that factors like tumor 
differentiation, lymph nodes status and tumor resection margins are 
correlated with poor prognosis of PDA patients. 
 
3.1.4 Pancreatic cancer and pancreatic cancer precursors 
Pancreatic ductal adenocarcinoma -PDA- is considered as 
synonym of  pancreatic cancer. At the gross level, PDA appears as 
firm sclerotic mass with poor defined borders. At the microscope 
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level, PDA cells are consisting of infiltrating gland-forming 
neoplastic epithelium surrounded by a strong desmoplastic 
reaction. The desmoplastic reaction is so usually strong that the 
neoplastic cells becomes a minority in the tumor. Infiltrative cells 
around neurons and vessels are dominantly recognized in resected 
tumors (R.H.  Hruban, Klimstra, & Pitman, 2006). PDA cells show 
similar cuboidal phenotype, express ductal antigens and grow in 
tubular structure like pancreatic ductal cells which led investigators 
to predict that exocrine cells are the origin of PDA (R.H.  Hruban, 
Klimstra, & Pitman, 2006). This theory was firstly proposed in 1976 
by Cubilla and Fitzgerald (Cubilla & Fitzgerald, 1976). They studied 
227 cases with pancreatic cancer and 100 autopsies from normal 
pancreas as a control. They observed that the occurrence of ductal 
papillary hyperplasia was three times more in pancreas cancers 
than in controls. Moreover, they found that the incidence of ductal 
papillary hyperplasia is 37% in PDA where it was 12% in control 
group. Also, they observed 20% with marked atypia and 18% with 
carcinoma in situ of the pancreas cancer cases, but these two 
features were absent in the control cases. Since then any pre-
cancerous lesion in pancreatic ductal cells is considered as a 
precursor of pancreatic cancer. The pre-cancerous lesions are 
divided in pancreatic intraepithelial neoplasia (PanIN), intraductal 
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papillary mucinous neoplasm (IPMN), and mucinous cystic 
neoplasm (MCN).  
 
PanIN lesions can be papillary or flat, and are composed of 
columnar to cuboidal cells with various amounts of mucin. Hruban 
et al. divided these lesions into three basic categories PanIN 1, 2, 3 
and PanIN 1 was divide to A and B depending upon the degree of 
cytologic and architectural atypia (Figure.1) (R. H. Hruban et al., 
2001; R. H. Hruban et al., 2004). Many researchers compared 
between genetic mutations in PDA and PanIN. Their studies 
showed a remarkable similarity of mutations depending on the 
PanIN degree, for example telomere shortening in PanIN1 (van 
Heek et al., 2002), overexpression of p53 in precancerous glands 
(Boschman, Stryker, Reddy, & Rao, 1994), inactivation of BRCA2 
in late stages of PanIN (Goggins, Hruban, & Kern, 2000), early loss 
of heterozygosity (LOH) of p16 (INK4) and late LOH of 
DCP4/SMAD4 (Heinmoller et al., 2000), overexpression of EGFR 
and Her-2/neu (ERRB2) (Day et al., 1996), and K-ras activation 
mutation (Terhune, Phifer, Tosteson, & Longnecker, 1998) 
(Figure.2). As so far, no valid method of pancreatic screening has 
been discovered. Identification of global gene expression is 
27 
 
suggested to be used as a biomarker to facilitate diagnosis and 
therapy (Sipos, Frank, Gress, Hahn, & Kloppel, 2009). 
 
Intraductal papillary mucinous neoplasm (IPMN) is another 
precursor of PDA. IPMN is defined as a mucin-producing epithelial 
neoplasm ranging from benign to invasive carcinoma. In 1984 
IPMN was firstly described by Ohhashi et al. in Japan, then after 
eight years IPMN was recognized in North-America (Belyaev et al., 
2008). IPMN is classified by WHO in many categories depending 
on the degree of the atypia architecture (Longnecker, Adler, & 
Hruban, 2000). IPMN consists of IPMN adenoma which show 
differentiated columnar cells displaying minor or no dysplasia; 
IPMN border-line which shows moderate dysplasia, moderate loss 
of polarity, nuclear crowding, nuclear enlargement, nuclear 
hyperchromatism, and pseudopapillary;  and IPMN carcinoma 
(carcinoma in situ) that displays sever dysplasia, mucin diminishing, 
cribriform growth, budding to the lumen, loss of polarity, loss of 
differentiation, cellular and nuclear polymorphism, nuclear 
enlargement and presences of mitosis. IPMN can arise from the 
main pancreatic duct (it can be invasive), or from secondary ducts, 
or even both (Nakagohri, Kenmochi, Kainuma, Tokoro, & Asano, 
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1999; Terris et al., 2000). IPMN carcinoma is predominantly 
consisting of colloid (mucinous noncytic) carcinoma, and the rest 
consists mainly of conventional tubular adenocarcinoma (Adsay, 
2002). IPMN shares many genetic abnormalities with PDA, for 
instance mutations of the KRAS2 (Z'Graggen et al., 1997), 
TP53/p53 (Islam et al., 2001; Sasaki et al., 2003) and CDKN2A/p16 
genes (Biankin et al., 2002), rare loss of SMAD4 expression 
(Biankin et al., 2002; Sasaki et al., 2003) and loss of STK11/LKB1 
gene (Sahin et al., 2003). Fortunately, IPMN has better diagnosis 
than PDA for producing radiographically identifiable ductal dilatation 
(Canto et al., 2006) and better diagnosis with surgical treatment, 
(Kanazumi et al., 2001).  
 
Finally, mucinous cystic neoplasm (MCN) which is also a 
mucin-producing epithelial neoplasm but harbor a distinctive 
ovarian-type stroma absent in IPMN (R.H.  Hruban, Klimstra, & 
Pitman, 2006).  
 
Although 20% of pancreatic cancer patients are susceptible 
for pancreaticoduodenectomy operation, resected pancreas 
29 
 
patients prognosis tends to deteriorate after the surgery. There are 
many factors that affect the prognosis outcome like tumor 
differentiation, tumor diameter, lymph nodes status, positive 
resection margins, surgery out with  specialist centers (Birkmeyer et 
al., 1999; Lim, Chien, & Earle, 2003; Sohn et al., 2000; Sperti, 
Pasquali, Piccoli, & Pedrazzoli, 1997; Yeo et al., 1997). Lately, 
other factors like systemic inflammation presence and node ratio 
were proposed to predict prognosis and adjuvant therapy plan 
(Jamieson et al., 2005; Riediger et al., 2009). 
 
3.1.5 Pancreatic cancer genetical progression 
Pancreatic cancer is defined as a pathology of accumulated 
of inherited or somatic mutations of oncogenes activation or tumor 
suppressor genes inactivation. Thanking to advanced technology, 
several genetical mutations were identified. As mentioned above, 
PanIN lesions, which are considered as precursors of PDA, harbor 
many but not all PDA genetical mutation (R. H. Hruban, Wilentz, & 
Kern, 2000). 
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3.1.5.1 KRAS 
KRAS is the most common mutated gene in pancreatic 
cancer occuring  in 90% of pancreatic cancer cases (Caldas & 
Kern, 1995). KRAS is a protooncogene activated by a mutation 
which permits KRAS product to play a crucial role in  a range of 
cellular functions, including proliferation, survival, and motility. The 
activation of KRAS protein initiates when growth factors bind to 
growth factor receptors which results a downstream signal 
transduction to activate KRAS. In the active state KRAS binds to 
guanosine triphosphate (GTP). Upon conversion of GTP to 
guanosine diphosphate (GDP) by guanosine triphosphatase-
activating protein (GAP), KRAS is turned off. Activating mutation 
prevents GAP from hydrolyzing GTP causing accumulation of 
active KRAS-GTP. Most of KRAS mutations occur in codon 12, 13, 
and 61 (Bos, 1989; Caldas & Kern, 1995). KRAS mutation is one of 
the earliest mutation in pancreatic cancer progression. 36% of 
PanIN-1A cases,  44% of PanIN-1B of cases and 87% PanIN-2/3 
cases demonstrate KRAS mutations (Maitra, Fukushima, Takaori, 
& Hruban, 2005).  Researchers have found that different PanINs in 
the same tumor can display different mutations suggesting that 
there are separate clonal evolution of multiple pancreatic 
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neoplasms within the same tumor (Moskaluk, Hruban, & Kern, 
1997). KRAS mutation has an important role in PDA progression 
which is proven through the high frequency of mutation in PDA 
patients and animal model studies which revealed that animals 
begin to develop pancreatic cancers when they carry a mutation in 
KRAS (Fleming, Shen, Holloway, Davis, & Brekken, 2005; 
Hingorani et al., 2003; Moskaluk, Hruban, & Kern, 1997). Beside 
the role of PDA developing, KRAS plays a major role in pancreatic 
cancer proliferation (Fleming, Shen, Holloway, Davis, & Brekken, 
2005). 
 
3.1.5.2 HER-2/neu 
HER-2/neu is a member of the epidermal growth factor 
receptor family and is over expressed in 69% of PDA cases (Day et 
al., 1996). Day et al. evaluated the expression of HER-2/neu in 
different pancreatic lesions and found a correlation between the 
increasing HER-2/neu expression and  the increasing of pancreatic 
duct atypia (Day et al., 1996).  
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3.1.5.3 p16 
The p16 tumor suppressor gene, which is also known as 
INK4, is the most inactivated gene in PDA, its loss seen in 95% of 
PDA cases (Caldas et al., 1994; Schutte et al., 1997). This 
inactivation leads to phosphorylation of many growth proteins which 
cause loss of cell cycle control and unchecked proliferation (Sohn & 
Yeo, 2000). p16 inactivation results by different mechanisms, 
including homozygous deletion, intragenic mutation with loss of the 
second allele and epigenetic silencing by promoter methylation 
(Maitra, Kern, & Hruban, 2006).  
 
3.1.5.4 TP53 
TP53 is a tumor suppressor gene, which is inactivated in 
approximately 50%-75% of pancreatic cancer (Redston et al., 
1994). The majority of the inactivation of TP53 gene occurs through 
intragenic mutation with loss of the second allele. In normal non-
stressful status p53 protein, expression is very low. However, when 
cells are exposed to DNA damage, hypoxia or other insults, p53 
becomes activated and induces growth arrest and/or apoptosis by 
the induction or repression of specific genes. In pancreatic cancer 
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cell, loss of p53 function permits the cell to survive and proliferate 
regardless of damaged DNA, which leads to more accumulation of 
additional genetic mutations (Vogelstein & Kinzler, 2004).  
 
3.1.5.5 DCP4/SMAD4 
Deleted in pancreatic carcinoma 4 gene (DPC4), which is 
also known as SMAD4, on chromosome 18q21 is inactivated in 
approximately 55% of PDA, either by homozygous deletion (30%) 
or by intragenic mutations and loss of the second allele (25%) 
(Hahn et al., 1996). Smad4 protein performs a crucial role in 
signaling through the transforming growth factor-β -TGF-β- 
pathway. The TGF-β pathways starts when the TGF-β protein 
adheres to TGF-β receptors. This provokes an intracellular cascade 
of phosphorylation and nuclear localization of the Smad 
transcription factors Smad 4 and Smad 2/3 complex. In normal 
condition the TGF-β pathway plays a growth-inhibitory role by 
controlling the expression of specific target genes, subsequently, 
deficiency of Smad4 in PDA cells allows the cancer cells to grow 
uncontrollably (Siegel & Massague, 2003). Loss of Smad4 
expression occurs only at PanIN-3 lesions, whereas almost all 
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noninvasive lesions maintain its expression (Iacobuzio-Donahue, 
Klimstra et al., 2000; Iacobuzio-Donahue, Wilentz et al., 2000; 
Wilentz, Iacobuzio-Donahue et al., 2000).  
 
3.1.5.6 BRCA2 
Patients with inherited tumor suppression gene BRCA2 
mutation are identified to be in a risk of developing breast, ovarian, 
prostate, stomach and malignant melanomas tumors ("Cancer risks 
in BRCA2 mutation carriers. The Breast Cancer Linkage 
Consortium", 1999; Hamilton, 2009; Liede, Karlan, & Narod, 2004; 
Ostrander & Udler, 2008; Ramus & Gayther, 2009). Additionally, 
the same patients have a relative risk of 3.51 (95% CI 1.87-6.58) of 
developing pancreatic cancer ("Cancer risks in BRCA2 mutation 
carriers. The Breast Cancer Linkage Consortium", 1999). Goggins 
et al recognized mutation in BRCA2 occurred late in the 
development of PDA, nevertheless this was a very small study of 
14 PanIN lesions with a single mutation (Goggins, Hruban, & Kern, 
2000). BRCA2 mutation is considered to occur late in pancreatic 
cancer cells, which can tolerate DNA damage, as BRCA2 loss 
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leads to lethal chromosomal abnormalities which is not tolerated in 
normal cells (Venkitaraman, 2002). 
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3.2 Caveolae and Caveolin  
3.2.1 Background 
The advent of caveolae research owes its inception to their 
morphological identification in 1953. By transmission electron 
microscopy, caveolae appear an structures resembling “little 
caves”, which are 50- 100-nm vesicular invagination of the plasma 
membrane (Figure.3) (Palade, 1953). Caveolin-1 (Cav-1 or VIP21) 
was the first family member identified, and was demonstrated as 
structural component of caveolae and trans-Golgi derived transport 
vesicles. Since then, caveolae/caveolin-related research has 
identified a family of three proteins, caveolin-1, -2, and -3, all of 
which serve as protein markers for caveolae. Caveolae are 
considered by many to be a subset of lipid rafts, these are highly-
ordered microdomains residing within the plasma membrane 
dramatically enriched in cholesterol and sphingo-lipids (glycol-
sphingolipids and sphingo-myelin) in comparison with the 
surrounding phospho-lipid bilayers (D. A. Brown & London, 1998; 
Galbiati, Razani, & Lisanti, 2001b; Simons & Toomre, 2000). 
However, the classification of caveolae as a subset of lipid rafts 
may be not be completely accurate, as some proteins are known to 
selectively localize to either lipid rafts or caveolae but not in both 
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(Liu, Ying, & Anderson, 1997). The particular biochemical 
properties of caveolae/lipid rafts are conferred by their lipid 
composition. This has enabled investigators to efficiently purify 
caveolae-enriched membrane fractions from cells and tissues by 
sucrose gradient ultracentrifugation due to i) their reduced density 
(high buoyancy) and ii) resistance to solubilization by mild non-ionic 
detergents (Triton X-100) at 4°C (Chang et al., 1994; Lisanti, 
Sargiacomo, & Scherer, 1999; Lisanti, Scherer, Tang, & 
Sargiacomo, 1994; Lisanti, Tang, Scherer, & Sargiacomo, 1995). 
The majority of caveolae in cells and tissues require only Cav-1 
expression for their proper formation, whereas Cav-2 is not 
absolutely required (Figure.3) (Drab et al., 2001; Razani, Combs et 
al., 2002; Razani et al., 2001). On the other hand, caveolae that are 
found in skeletal muscle tissue and cardiac myocytes are mainly 
Cav-3 generated (Figure.3) (Galbiati, Engelman et al., 2001; 
Razani, Woodman, & Lisanti, 2002).  
 
3.2.2 Gene organization and evolution history 
The structural component of caveolae remained unknown for 
many decades until a 22 KDa protein was isolated as one of 
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several proteins that became tyrosine-phosphorylated in v-Src-
transformed chicken embryo fibroblasts (Glenney & Zokas, 1989). 
this protein was later termed caveolin (now renamed caveolin-1; 
(Scherer et al., 1996)) since monoclonal antibodies directed against 
this protein decorated the cytoplasmic protein coat of caveolae. As 
a result, caveolin-1 was identified as the first true protein marker of 
caveolae.  
Subsequent cloning of caveolin-1 cDNA revealed that it was 
identical to another protein, known as VIP21, which had been 
cloned almost simultaneously (Glenney, 1992; Kurzchalia et al., 
1992). Interestingly, VIP21 was isolated as an integral membrane 
protein component of trans-Golgi derived transport vesicles in 
MDCK cells, suggesting that caveolin-1/VIP21 may also possess a 
role in molecular trafficking, as well as oncogenesis. Since then, 
caveolin-1 (Cav-1) has been found to be expressed ubiquitously, 
albeit diversely, with the highest levels in adipocytes, endothelial 
cells, fibroblasts, smooth muscle cells, and a variety of epithelial 
cells. In accordance with this observation, it has become clear that 
the cellular functions of caveolin-1 are dependent on the cellular 
context.  
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Since the cloning of the first caveolin-1 cDNA sequence from 
a chicken genomic library by Glenney and Soppet in 1992 
(Glenney, 1992), numerous other caveolin-1 sequences have been 
obtained from a whole range of vertebrates, including humans, 
bovine, dog, mouse, Xenopus, and the Japanese pufferfish Fugus 
rubripes (Table.2). These cloning efforts also identified a caveolin 
gene family within invertebrates, specifically C. elegans, 
demonstrating the ubiquity of caveolins among higher-evolved 
organisms (Scheel, Srinivasan, Honnert, Henske, & Kurzchalia, 
1999). 
 
Caveolin-2 and caveolin-3 were identified in 1996 through 
different experimental methods. Caveolin-2 (Cav-2) was discovered 
by micro-sequencing of a 20 KDa protein that co-purified with 
adipocytes-derived caveolae membranes (Scherer et al., 1996). 
Further characterization revealed that cav-2 co-localizes with cav-1 
in caveolae, forms hetero-oligomers with cav-1, is co-expressed in 
many of the same cells and tissues, and requires cav-1 for proper 
transport from the Golgi apparatus to the plasma membrane 
(Parolini et al., 1999; Scherer et al., 1997). Caveolin-3 (Cav-3) was 
identified through data-base searches and traditional cDNA library 
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screening in an attempt to find cav-1 homologous (Tang et al., 
1996). Cav-3 (also known as M-caveolin) is an interesting member 
of the caveolin gene family, as it is expressed predominantly in 
striated muscle cells (Song, Scherer et al., 1996). 
 
The three mammalian genes encoding members of the 
caveolin family share significant homology. The cav-2 protein is 
approximately 38% identical and 58 similar to cav-1, while cav-3 is 
more closely related to cav-1, with 56% identity and 85% similarity 
(Table.3). Interestingly, however, cav-1 and cav-2 are located in 
very close proximity to each other on human chromosome 7q31.1, 
while cav-3 is located on a different chromosome (3p25). Cav-1 is 
located ~ 19 kb downstream of cav-2 on chromosome 7q31.1, while 
cav-2, in turn is located ~67 kb downstream from the D7S552 
microsatellite locus (Engelman, Zhang, Razani, Pestell, & Lisanti, 
1999). Intriguingly, this D7S552 microsatellite repeat marks a 
region commonly deleted in human cancers (Engelman, Zhang, 
Galbiati, & Lisanti, 1998). This genetic observation implicated cav-1 
as a potential tumor suppressor, when taken together with the other 
functional data showing that cav-1 possesses transformation-
suppressor activity in cultured cells (Koleske, Baltimore, & Lisanti, 
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1995). Deletion or mutation of the cav-3 gene on chromosome 
3p25 is also associated with a human disease, namely autosomal 
dominant Limb-girdle Muscular Dystrophy, Type-1C (LGMD-1C) 
(Minetti et al., 1998).  
 
The phylo-genetic relationship among caveolin family 
members is shown using the Clustal-W program, with the C. 
elegans cav-1 sequence located the furthest in terms of predicted 
evolutionary distance (Figure.4). While the evolutionary  history of 
the caveolin genes has not been clearly defined, there are clues 
present within the sequence and genomic organization that suggest 
possible mechanisms for the origin of the individual genes. One 
interesting observation made from C. elegans is that while C. 
elegans cav-1 contained two exons, the region that is homologues 
to mammalian caveolin is encoded by only single exon, suggesting 
that mammalian caveolins are derived from this particular exon 
(Tang et al., 1997). Another point is that the overall genomic 
organization of the cav-1 and cav-2 is relatively conserved from 
humans to pufferfish. However, there is a significantly higher 
degree of homology between human cav-1 and Fugu cav-1, when 
compared to human cav-2 and Fugu cav-2. This may suggest that 
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cav-2 can tolerate more sequence diversity (a higher mutation 
rate), despite being located at the same genetic locus (Engelman, 
Zhang, & Lisanti, 1999). Finally, two observation extracted from the 
human genomic sequence insinuate that some family members 
may have arisen through gene duplication events: i) the exon-intron 
boundaries in the last exons of cav-1 and cav-2 are analogues; ii) 
exon 2 of cav-2 is divided into two parts (named 2a and 2b) by an 
intron whereas the two homologues portions in the cav-1 and cav-3 
sequences are fused together to form the final exon(Engelman, 
Zhang, & Lisanti, 1998, , 1999). this second point suggests that 
cav-2 may be the precursor for cav-1 and cav-3 (Williams & Lisanti, 
2004). 
 
3.2.3 Characteristics structural features 
While research has begun to provide insights into the 
genetics of caveolins, the structural features of this protein family 
are poorly defined. Currently, there exists no crystallographic data 
that could suggest a three dimensional structure of any caveolin 
family member. However, information gleaned from the protein 
sequence has allowed predictions of structure and motifs within the 
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protein. For instance, all three caveolins possess an invariant 
“FEDVIAEP” stretch within their hydrophilic N-term domains that 
has come to be termed the “caveolin signature motif” (Scherer et 
al., 1996; Tang et al., 1996). However, the importance of this 
sequence or motif has yet to be determined. The majority of the 
remaining structure-related research has focused on cav-1 as the 
proto-typical family member.  
 
Through a variety of experimental methods, it has been 
determined that the major sub-cellular location of cav-1 is at the 
plasma membrane. Based on a combination of primary sequence 
(hydrophilicity plots) and mutational analysis, cav-1 is predicted to 
have a membrane-spanning hairpin-like structure, with both N- and 
C-terminus directed intracellularly towards the cytoplasm (Figure.5). 
This typical membrane spanning model is supported by the findings 
that i) antibodies directed against the cav-1 N- or C-terminus 
require permeabilization of cells in order to bind cav-1, ii) cell 
surface biotylation does not label cav-1, and that there are well-
known palmitoylation and tyrosine phosphorylation sites within both 
N- and C-terminal domains of the protein (Dietzen, Hastings, & 
Lublin, 1995; H. Lee et al., 2000; S. Li, Seitz, & Lisanti, 1996; 
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Sargiacomo et al., 1995). Palmitoylation and tyrosine 
phosphorylation are both cytoplasmically generated post-
translational modifications. 
 
Among caveolins, the predicted domains virtually span the 
same number of residues. The N-terminal domain comprises the 
first 70-101 residues (cav-1= 101 residues, cav-2/cav3= 70-74 
residues), with the putative transmembrane domain occupying 32 
amino acids, and the C-terminal domain 42-44 amino acids. 
Interestingly, two cav-1 isoforms (α and β) have been identified, 
with the β-isoform arising from an internal translational start site 
that generates a shorter cav-1 isoform, with a 31 residue truncated 
N-terminus (Scherer et al., 1995).  
  
Generally speaking caveolins are small proteins (18-24 
KDa). Structurally, perhaps one of the most interesting and 
significant findings about cav-1 is that it forms an oligomeric 
complex comprised of approximately 14 to 16 monomers. The 
discovery that cav-1 exists as a high molecular mass complex was 
achieved through velocity gradient ultracentrifugation. By this assay 
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system, cav-1 was found to migrate as a 350-400 KDa complex, 
composed exclusively of cav-1 (Sargiacomo et al., 1995). In 
addition, experiments with cav-1 deletion mutants mapped this 
“oligomerization domain” to residues 61-101 (Figure.6). 
Interestingly, also cav-3 forms large ~350-400 KDa oligomeric 
complexes in vivo, while cav-2 requires cav-1 to participate in the 
formation of these higher molecular mass complexes.  
 
Moreover, cav-1 contains a region within the oligomerization 
domain that is presumed to be the main functional domain of 
caveolin family members. This region, spanning cav-1 amino acid 
positions 82-101 (Figure.6), has been termed “the caveolin-
scaffolding domain” (CSD) since it mediates binding of a number of 
signaling proteins (S. Li, Couet, & Lisanti, 1996; Scherer et al., 
1997). The CSD behaves as a modular protein domain, akin to 
SH2/SH3 and WW domains, and allows the binding of multiple 
classes of signaling molecules, including Src-family tyrosine kinase, 
eNOS, receptor tyrosine kinases (such as Insulin-R, EGFR, 
ErbB2/Neu, PDGFR), H-Ras, PKC isoforms, and PKA (Razani, 
Woodman, & Lisanti, 2002; Scherer et al., 1997). Aside from acting 
as a scaffolding protein to compartmentalize these signaling 
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molecules, this region of cav-1 appears to inhibit the down-stream 
activation and signaling of many of these proteins (Razani, 
Woodman, & Lisanti, 2002). Screening of random peptide libraries 
using the caveolin-scaffolding domain receptor, has identified 
caveolin-binding-motifs on other proteins that mediate their high 
affinity association with the CSD (Couet, Li, Okamoto, Ikezu, & 
Lisanti, 1997). These caveolin-binding motifs consist of a series of 
3-or-4 aromatic amino acids (Tryptophane –W-, phenylalanine –F-, 
and tyrosine –Y-), with a particular spacing.  
 
3.2.4 Localization and Function 
Beginning with its early characterization, cav-1 was shown to 
localize to plasma membrane caveolae, demonstrating a punctate 
staining pattern at the margins of cells (Glenney, 1992). 
Additionally, Simons et al have shown positive staining of the Golgi 
apparatus and trans-Golgi-derived transport vesicles (Kurzchalia et 
al., 1992). Since then, recent research has built upon the notion 
that caveolin localization is limited to membranes and vesicles by 
providing new evidence that cav-1 also exists in a soluble 
cytoplasmic form, as wells as a secreted form, depending on the 
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cell type (Liu, Rudick, & Anderson, 2002). While there are no N-
terminal signal sequences in cav-1, the finding that the β-isoforms 
of cav-1 is targeted to the cytosol in skeletal muscle cells but hint at 
the importance of the first 31 amino acids in selectively targeting 
cav-1 to different cellular compartments (W. P. Li, Liu, Pilcher, & 
Anderson, 2001).  
 
Cav-1 and cav-2 are tightly co-expressed in a diverse range 
of cells and tissues, suggesting that both utilize identical 
transcription regulatory pathways. Interestingly, cav-1 is required 
for proper membrane localization of cav-2. For example, when cav-
2 is expressed in the absence of cav-1, cav-2 retained in the Golgi 
complex and rapidly degraded (Parolini et al., 1999). A mutant form 
of cav-1 found in up to 16% of human breast cancers, Cav-1 
(P132L), has a single-amino acid substitution in the membrane-
spanning region (Hayashi et al., 2001). Therefore, does not 
properly localize to the plasma membrane (H. Lee et al., 2002). 
Furthermore, cav-1 (P132L) behaves in a dominant-negative 
manner, causing the mis-localization and intracellular retention of 
wild-type cav-1 (H. Lee et al., 2002). Intriguingly, an analogous P-
to-L mutation at position 104 within cav-3 has been detected in 
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patients with LGMD-1c. This mutation also behaves in a dominant-
negative fashion (Galbiati, Razani, & Lisanti, 2001a; Galbiati, 
Volonte, Minetti, Bregman, & Lisanti, 2000; Minetti et al., 1998; 
Parolini et al., 1999). Wild type cav-3 also localizes to caveolae and 
the plasma membrane, but its tissue-specific expression in muscle 
cells led to the observation that cav-3 also associates with the T-
tubule network (Minetti et al., 2002). In fact, cav-3 (-/-) deficient 
mice develop abnormalities in the organization of the T-tubule 
system, and clearly lack sarcolemmal caveolae in skeletal muscle 
fibs and cardiac myocytes (Galbiati, Engelman et al., 2001). 
 
The upsurge in caveolin-related research has helped to 
clarify the existing purported functions of caveolae and identify new 
functions of these structures and their associated proteins. It is 
becoming clear that different caveolin proteins may have distinct 
role in certain cells types and tissues that are completely unrelated 
to their roles in other cells. The following are brief description of 
some of the functions of caveolins.  
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3.2.5 Vesicular transport 
Numerous lines of research have implicated caveolae in the 
processes of vesicular trafficking e.g., transcytosis, endocytosis, 
and potocytosis. Their profuse appearance on both apical and 
basolateral faces of endothelial cells first suggested a role for 
caveolae in the process of transcytosis. Since that time, endothelial 
caveolae have now been shown to possess the molecular 
components utilized by other transport vesicles, during the 
processes of vesicle formation, docking and fusion, including 
vSNARE VAMP-2, GTPases, NSF and SNAP (S. W. Lee, Reimer, 
Oh, Campbell, & Schnitzer, 1998). In addition, dynamin localizes to 
caveolae and is concentrated at their caveolar necks, suggesting 
that dynamin is responsible for caveolae fission and the formation 
of intracellular caveolar vesicles, a.k.a, plasmalemmal vesivles 
(Henley, Krueger, Oswald, & McNiven, 1998). In terms of 
endocytosis, it appears that certain ligands and extracellular 
molecules such as cholera and tetanus toxins, are transported 
through caveolae, rather than via clathrin-dependent mechanisms 
(Montesano, Roth, Robert, & Orci, 1982). Finally, micro-organisms 
appear to have evolved mechanisms to gain cellar entry through 
caveolae, including SV40 and certain strains of E. coli (Norkin, 
50 
 
2001). For additional information on this topic, the reader is referred 
to a more detailed review of caveolae and endocytosis (Pelkmans 
& Helenius, 2002).  
 
3.2.6 Cholesterol homeostasis 
Research clearly demonstrates an intimate relationship 
between cholesterol, caveolin proteins, and caveolae organelles. 
Cav-1 is one of the few proteins that tightly binds cholesterol, in a 
very specific fashion (Murata et al., 1995). In addition, free 
cholesterol is required for proper caveolae formation, as brief 
treatment of cells with cholesterol-binding agents, such as nystatin 
and filipin, disrupt caveolae structure and function (Smart et al., 
1999). In addition, the cav-1 promoter (Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999) contains two sterol regulatory elements 
(SREs) that are necessary for transcriptional activity by free 
cholesterol, through the transcription factor SREBP-1 (Bist, 
Fielding, & Fielding, 1997). This transcriptional relationship may 
have evolved due to the observation by Smart et al that newly 
synthesized cholesterol utilizes cav-1 and caveolae to be 
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transported to the cell membrane (Mineo, James, Smart, & 
Anderson, 1996).  
 
In terms of cholesterol homeostasis, caveolae have also 
been implicated in reveres cholesterol transport, the process during 
which excess free cholesterol is released into plasma via uptake by 
HDL particles. Evidence supporting this relationship includes: i) 
excess cholesterol appears in caveolae when cells are loaded with 
cholesterol; ii) anti-sense cav-1 reduces cholesterol efflux; and iii) 
adenoviral delivery of cav-1 to the liver results in increased plasma 
HDL cholesterol levels (Razani, Woodman, & Lisanti, 2002). in 
direct corroboration of these findings, SR-BI, a major receptor 
involved in cholesterol efflux to HDL, is significantly enriched within 
caveolae (Babitt et al., 1997). Finally, caveolae also appear to be 
involved in the uptake of cholesterol esters from the plasma 
(Fielding & Fielding, 2001).  
 
3.2.7 Signal transduction 
The establishment of a technique to isolate caveolae by 
virtue of their unique biochemical properties enabled large-scale 
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identification of other proteins residing in these membrane 
structures (Sargiacomo, Sudol, Tang, & Lisanti, 1993). Caveolae 
have now been demonstrated to concentrate a wide variety of 
proteins and signaling molecules including GPI-linked proteins, Src-
family tyrosine kinase, H-Ras, hetereotrimeric G-proteins alpha 
subunit, PKC isoforms, and eNOS (for the complete list see 
(Razani, Woodman, & Lisanti, 2002)). Interestingly, a large number 
of these molecules have been demonstrated to interact directly with 
cav-1, many through a defined motif that has come to be termed 
the caveolin scaffolding domain (CSD, residues 82-101) (Couet, Li, 
Okamoto, Ikezu, & Lisanti, 1997). This led to the establishment of 
the “caveolin signaling hypothesis”, stating that caveolae/caveolin-1 
do not solely function to compartmentalize and concentrate other 
proteins but also have a functional role in modulating signal 
transduction (Lisanti, Scherer, Tang, & Sargiacomo, 1994). 
 
Direct proof of this notion was provided in several landmark 
experiments demonstrating that cav-1 directly inhibited activation of 
proto-typical cavolar residents, hetero-trimeric G proteins (S. Li et 
al., 1995). Since then, cav-1 has been shown to negatively regulate 
signaling of many other proteins, including eNOS (Garcia-Cardena 
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et al., 1997), EGFR (Couet, Sargiacomo, & Lisanti, 1997), Src 
tyrosine kinases (S. Li, Couet, & Lisanti, 1996), H-Ras (Engelman 
et al., 1997), and Neu (Engelman, Lee et al., 1998). These negative 
regulatory relationships are also preserved in vivo: cav-1 (-/-) 
deficient mice demonstrate the physiological hyper-activation of 
eNOS within their vasculature (Razani et al., 2001). Undoubtedly, 
the ability of cav-1 and caveolae to modulate signaling has 
important implications for signaling in transformed, neoplastic cells. 
The data for cav-2 as a signaling modulator is less clearly defined, 
perhaps due partly to more divergent CSD sequence. However, the 
cav-3 CSD maintains considerable homology to cav-1, and cav-
3generated caveolae have been shown to compartmentalize and 
modulate a number fo signaling proteins, including eNOS, β-
adrenergic receptors, PKC isoforms, G-proteins, Src-family 
kinases, and multiple components of the dystrophin-glycoprotein 
complexes (α-sarcoglycan, β-dystroglycan, and dystrophin) 
(Razani, Woodman, & Lisanti, 2002).  
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3.2.8 Cellular proliferation 
The observation that cav-1 is expressed at the highest levels 
in terminally differentiated, relatively quiescent cells such as 
adipocytes, endothelium, smooth muscle cells and Type I 
penumocytes first a role for cav-1 in cell proliferation. Several 
groups have now demonstrated a role for cav-1 in cell cycle 
progression. Lee et al have documented that cav-1 levels are 
regulated during the cell cycle (S. W. Lee, Reimer, Oh, Campbell, & 
Schnitzer, 1998). In C. elegans, a role for cav-1 in meiotic cell cycle 
progression has been established (Scheel, Srinivasan, Honnert, 
Henske, & Kurzchalia, 1999). Galbiati et al have shown that cav-1 
levels are regulated by growth factor stimuli and that 
overexpression can inhibit proliferation in mediating cell cycle arrest 
in G0/G1 (Galbiati, Volonte et al., 2001). Additionally, our laboratory 
has reported that in mouse embryonic fibroblasts (MEFs), genetic 
ablation of cav-1 results in increased proliferation rates concomitant 
with increased S-phase and decreased G0/G1 fraction, as well as 
altered expression of several cell cycle-related proteins (Razani et 
al., 2001; Williams et al., 2004). 
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Elucidation of the mechanisms by which cav-1 exerts 
negative regulatory effect on proliferation has uncovered a few of 
the molecular pathways involved. Cav-1 demonstrated to cause 
transcriptional suppression of Cyclin D1 an important regulatory 
component of the cyclin-cdk complex that phosphorylates Rb, 
thereby controlling entry into the S phase (Hulit et al., 2000). 
Furthermore, we have demonstrated that the induction of G0/G1 
arrest by cav-1 overexpression appears to operate through a 
p53/p21Cip1 dependent pathway (Galbiati, Volonte et al., 2001). 
 
The large majority of research on cav-1 and proliferation has 
centered on the ERK-1/2 (p42/44 MAP kinas) mitogenic signaling 
cascade. Many components of the ERK signaling cascade appear 
to be localized in caveolae, including growth factor receptors such a 
EGFR, TGF-βR, Ras, Ras-1, MEK, and ERK (Liu, Ying, & 
Anderson, 1997; Liu, Ying, Ko, & Anderson, 1996; Mineo, James, 
Smart, & Anderson, 1996; Rybin, Xu, & Steinberg, 1999; Smart, 
Ying, Mineo, & Anderson, 1995; Song, Li et al., 1996). Additionally, 
recombinant cav-1 inhibits activation and signaling ERK 1/2 to the 
nucleus both in vitro  and in vivo (Engelman, Chu et al., 1998). In 
cells, down-regulation of cav-1 or genetic ablation of cav-1 has 
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been shown to be sufficient to result in constitutive hyperactivation 
of ERK 1/2 (Galbiati et al., 1998). Furthermore, hyperactivated ERK 
1/2 has also been detected in vivo in cav-1 (-/-) mice under various 
condition (Capozza et al., 2003; Cohen et al., 2003). Interestingly, 
there appears to be a reciprocal relationship between ERK and 
cav-1, since activation of the ERK 1/2 cascade down-regulates cav-
1 expression (Engelman, Zhang, Razani, Pestell, & Lisanti, 1999). 
Taken together, it appears that one of the function of cav-1 is to 
negatively regulate activation of the ERK 1/2 cascade.   
 
3.2.9 Caveolin-1 and Apoptosis 
Cell, including tumor cells, constantly face the decision of 
whether to survive and proliferate or commit to apoptosis, or 
programmed cell death. Therefore, identifying the signals or 
pathways inside a cell that are pro-apoptotic or anti-apoptotic has 
important implications for controlling tumor cell growth. 
Unfortunately, the evidence of the role of cav-1 in apoptosis is 
somehow contradictory and disparate. On the one hand, caveolae 
are highly enriched in both sphingomyelinase, the enzyme 
responsible for generating ceramide (Liu & Anderson, 1995). 
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Ceramide induces cell death by inhibiting the activation if the well-
characterized anti-apoptotic/survival pathway phosphatidylinositol 
3-kinase (PI3-K)/AKT (Zundel & Giaccia, 1998). Interestingly, cav-1 
has been shown to interact with the PI3K and cav-1 overexpression 
sensitizes fibroblasts to ceramide-induced death through a PI3-K-
dependent mechanism (Zundel, Swiersz, & Giaccia, 2000). 
Furthermore, Cai et al mentioned an alternative pathway that cav-1 
can sensitize cancer cells to drugs by inhibition of P-glycoprotein, 
which is an drug efflux transporter (Cai & Chen, 2004).  
 
On the other hand, negative regulation of cav-1  activity 
through distribution of caveolae by cholesterol-sequestering agents 
has been shown to block IL-6 and IGF-1induced activation of the 
PI3-K/AKT signaling pathway (Podar et al., 2003). Therefore, 
caveolae and cav-1 are required to mediate proper survival signals 
through the PI3-K/AKT pathway. Moreover, cav-1 overexpression in 
Rat1 cells and human prostate cancer cells (LNCaP), or cav-1 up-
regulation I androgen-insensitive LNCaP clones renders these cells 
more resistant to apoptosis (Timme et al., 2000; Tso et al., 2000). 
In addition, anti-sense down-regulation of cav-1 results in prostate 
cancer cells that are more sensitive to apoptosis (Tso et al., 2000). 
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Finally, Li et al have demonstrated that cav-1 overexpression 
mediates cell survival by sustaining activation of Akt through 
binding and inhibition of the serine/theronine protein phosphatases 
PP1 and PP2A (L. Li, Ren, Tahir, Ren, & Thompson, 2003). Taken 
together, these results argue that cav-1 has anti-apoptotic activities. 
 
The apparent incongruity of pro-apoptotic or anti-apoptotic 
function of cav-1 can be explained by cell-type specific roles for 
cav-1 (i.e. anti-apoptotic in prostate cancer cells) or may be due to 
the use of different inducers of apoptosis. In summary, these 
finding define multiple cell-type and apoptotic pathway-specific 
roles for cav-1 in cell survival and death. 
 
3.2.10 Caveolin-1 and transformation 
An inverse relationship between cav-1 expression and 
transformation has now been clearly established. During the initial 
characterization of cav-1, it was demonstrated that cav-1 levels 
were reduced in transformed cells and that the level of cav-1 
inversely correlated with soft agar growth (Koleske, Baltimore, & 
Lisanti, 1995). Subsequently, multiple groups demonstrated that 
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forced re-expression of cav-1 could significantly attenuate soft agar 
(anchorage independent) growth in transformed cells (Engelman et 
al., 1997; S. W. Lee, Reimer, Oh, Campbell, & Schnitzer, 1998; 
Razani et al., 2000). Interestingly, reductions of cav-1 by an anti-
sense strategy were sufficient to induce a transformed phenotype in 
NIH-3T3 cells, allowing these cells to grow in soft agar and form 
tumors in immunodeficient mice (Galbiati et al., 1998). Furthermore, 
another group has recently demonstrated that cav-1 
haploinsufficiency achieved through a retrovirus-mediated gene 
trapping approach is sufficient to induce partial transformation in 
human breast epithelial cells (Zou, McDaneld, & Smith, 2003).  
 
The utilization of cav-1 null mice has provide molecular 
genetic evidence contributing to the notion that cav-1 serves as an 
anti-transformative agent in many tissue. Cappozza et al  show that 
the skin of cav-1 (-/-) mice is more susceptible to chemical 
carcinogenic treatment, resulting in the formation of benign 
epidermally-derived tumors (Capozza et al., 2003). In addition, 
Williams et al demonstrated that the loss of cav-1 accelerates the 
appearance for mammary dysplastic lesions in tumor prone 
transgenic mice (Williams et al., 2003). Finally, genetic ablation of 
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cav-1 in MEFs renders them more susceptible to transformation 
and in vivo tumorigenesis with transforming oncogenes (Williams et 
al., 2004). Through the use of mice lacking one or both alleles of 
cav-1, these reports mimic the effects of naturally occurring 
inactivating genetic mutations.  
 
3.2.11 Tumor suppressor and oncogenes 
Research on the relative relationship of cav-1 to other 
cellular oncogenes and tumor suppressors bears importance for the 
intrinsic working of the cells. The multi-step nature of cellular 
transformation involves the acquisition of genetic alteration that 
ultimately affect the transcription, translation, or post-translational 
regulation of proteins, the functional end-product of DNA. These 
mutations can be transmitted through the germline, or can be 
acquired somatically during the lifetime of a cell. Two important 
properties of neoplastic cells are immortalization and 
transformation. In some sense, all cells within a microenvironment 
are undergoing the process of natural selection, and the cells that 
are able to more  quickly attain those two properties will more likely 
survive and propagate. Therefore, it is important to determine the 
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relative contributions of different genes in promoting immortalization 
or transformation.  
 
While cav-1 does not appear to have a direct role in 
immortalization, cav-1 does synergize with other immortalizing 
genes. Loss of the INK4 locus, which lost in 95% of pancreatic 
tumors –as we previously explained- (Caldas et al., 1994; Schutte 
et al., 1997), encoding both p16INK4a and p19ARF, is sufficient for 
certain cells to become immortalized. Williams et al  demonstrated 
that concomitant loss of cav-1 with INK4a, results in cells with a 
proliferative advantage, demonstrating that the loss of cav-1 
expression cooperates or synergizes with the genetic mutations 
that abolish INK4a function (Williams et al., 2004). Furthermore, 
transformation of immortalized cells INK4a (-/-)/cav-1 (-/-) with 
various oncogenes renders these cells more neoplastic, with large 
in vivo tumor burden. This data suggests that mutations or down-
regulation of cav-1 expression in certain cell types, in combination 
with an INK4a mutation, would impart cells with a profound 
neoplastic advantage over those cells with a mutation in either 
gene alone. 
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Another well-characterized tumor suppressor, p53, appears 
to be directly involved in regulating cav-1 expression. Razani et al 
have demonstrated that p53, which is inactive in 75% of pancreatic 
cancer, is a positive transcriptional and translational regulator of 
cav-1, and that inactivation of p53 through viral oncoproteins results 
in reduced cav-1 expression (Razani et al., 2000). cav-1 levels are 
also dramatically reduced in p53-deficient cells (S. W. Lee, Reimer, 
Oh, Campbell, & Schnitzer, 1998).  
  
A whole host of cellular oncogenes have been shown to 
reduce cav-1 expression in cells (Tabel.4). These include, but are 
not limited to, c-Myc, HPV E6, v-abl, bcr-abl, H-RasG12V, v-Src, 
Neu/ErbB2 (Engelman, Lee et al., 1998; Koleske, Baltimore, & 
Lisanti, 1995; Park et al., 2001; Razani et al., 2000; Timme et al., 
2000). Virtually all of these oncoproteins appear to down-regulate 
cav-1 expression through a transcriptional mechanism. Additionally, 
Ras and Raf-mediated downregulation of cav-1 relies upon ERK 
1/2 activation as ERK 1/2 inhibition restores cav-1 expression in 
Ras and Raf-mediated cells as well as in human fibrosarcoma cells 
(Engelman, Zhang, Razani, Pestell, & Lisanti, 1999; Wiechen et al., 
2001). Activation of non-oncogenic proteins have also been 
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demonstrated to down-regulated cav-1 expression, including PKA 
and PKC alpha (Engelman, Zhang, Razani, Pestell, & Lisanti, 1999; 
Xie, Zeng, Waldman, & Glazer, 2003).  
 
3.2.12 Cavolin-1 in human cancers 
The human chromosomal location of the cav-1 gene has 
been mapped closely to the D7S522 microsatellite repeat marker 
locus on 7q31.1 (Engelman, Zhang, & Lisanti, 1998). The 
observation that this region is commonly deleted in a number of 
human cancers, including carcinomas of the pancreas, breast, 
colon, kidney, prostate, ovary, head and neck has led to hypothesis 
that this region encodes a tumor suppressor locus (Achille et al., 
1996; Matsuura et al., 1998; Zenklusen, Bieche, Lidereau, & Conti, 
1994; Zenklusen, Thompson, Klein-Szanto, & Conti, 1995; 
Zenklusen, Thompson, Troncoso, Kagan, & Conti, 1994; 
Zenklusen, Weitzel, Ball, & Conti, 1995).  
 
However, sequence analysis of cav-1 in human tumors has 
so far revealed only a few mutations. As previously mentioned, 
Hayashi et al. detected a sporadic P132L mutation in up to 16% of 
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patients with primary breast cancer (Hayashi et al., 2001). 
Molecularly, this mutation induces cellular transformation, acts in a 
dominant negative fashion by causing mislocalization and 
intracellular retention of wild-type cav-1, and causes ERK activation 
(Hayashi et al., 2001; H. Lee et al., 2002). Interestingly, this 
mutation appears in he analogous residue (P104L) in cav-3 in 
patients with an autosomal dominant form of limb-girdle muscular 
dystrophy (Minetti et al., 1998). Independently, another group has 
identified novel cav-1 mutations in human oral squamous cell 
cancer (S. E. Han, Park, Lee, Huh, & Min, 2004). These mutations 
await further molecular characterization.  
 
Cav-1 has now been implicated in a wide range of human 
tumors. Interpretation of the cellular data on inhibition of 
transformation by cav-1 proposes that the majority of human 
tumors would demonstrate reduced levels of cav-1. This is clearly 
true for other proteins, such as the well characterized p53 or Rb 
tumor suppressors, where a consistent pattern on down-regulation 
or inactivating mutation of one or both alleles is observed across a 
large variety of tumor types. On the contrary, cav-1 expression level 
is not consistently down-regulated in the majority of human tumor 
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types. However, within tumor types derived from the same cell type 
or tissue, cav-1 expression levels are consistently wither up-
regulated or down-regulated in the majority of cases. For instance, 
cav-1 down-regulation is typical of ovarian, lung and mammary 
carcinomas, as well as mesenchymal sarcomas. On the other 
hand, cav-1 is consistently up-regulated in bladder, esophagus, 
thyroid, and prostate carcinomas. As there are always exceptions 
to the rule, cav-1 expression has been detected in intraductal and 
infiltrating breast carcinomas, while some androgen-insensitive 
prostate cancer cells demonstrate reduced cav-1 levels (Pflug, 
Reiter, & Nelson, 1999; Yang et al., 1998). Variable expression 
patters have been observed in colon, renal, oral and pancreatic 
carcinomas. Further research will assist in identifying the modifying 
factors that determine whether it is the up-regulation or down-
regulation of cav-1 in these latter tumor types that facilitates 
tumorigenesis.  
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3.2.13 Caveolin-1 and pancreatic cancer 
Although little is known about cav-1 in pancreatic cancer. 
cav-1 data shows contradiction between in vivo and in vitro. 
Although Suzuoki et al found that cav-1 is a negative predictor of 
survival as it positively correlates with tumor diameter, 
histopathologic grade and poor prognosis (Suzuoki et al., 2002), on 
the other hand, several in vitro studies described cav-1 role as a 
tumor suppressor molecule. Indeed, Lin et al showed that cav-1 
inhibits migration and invasion ability of pancreatic cancer cell lines 
(Lin, DiVito, Merajver, Boyanapalli, & van Golen, 2005), And Han et 
al mentioned that cav-1 decreases invasion through inhibition of 
matrix metalloproteinases (MMPs) (F. Han & Zhu, 2009). Moreover, 
Han et al showed that cav-1 decreases tumor growth in nude mice 
(F. Han, Gu, Chen, & Zhu, 2009). This contradiction of data 
encouraged us to investigate and verify the cav-1 role through 
several  in vitro and in vivo studies. 
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3.3 Epithelial-mesenchymal transition 
3.3.1 Introduction 
Epithelial-mesenchymal transition (EMT) is a biological 
process where it allows polarized arranged epithelial cells, which 
are connected to a basement membrane on the basal side, to 
undergo through biochemical and molecular alteration to gain a 
mesenchymal cell phenotype. EMT was first described by Elizabeth 
Hay when she noticed transformation of epithelial cells to 
mesenchymal and vice versa using chick primitive streak formation 
model (Hay, 1995). While epithelial can change to mesenchymal 
and vice versa due to cell plasticity, the word transformation has 
changed to transition. EMT is initiated by variant molecular 
processes such as various transcriptional factors, expression or 
loss of membranous proteins, reorganization if cytoskeletal proteins 
and production of extracellular matrix enzymes. Kalluri et al 
proposed three different biological subtypes of EMT, based in the 
biological cell context (Kalluri & Weinberg, 2009). Type 1 EMT is 
associated with implantation, embryo formation, and organs 
development, in this type epithelial cells transit to mesenchymal 
and vice versa -mesenchymal-epithelial transition- (MET); type 2 
EMT is associated with inflammation, fibrosis and wound healing; 
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type 3 EMT occurs in neoplastic cells, which is characterized by 
high migratory and invasiveness potential, elevated apoptosis and 
drug resistance and increased production of extracellular matrix 
(ECM) (Figure.7) (Kalluri & Weinberg, 2009). Various molecular 
alterations are accompanied with EMT process which allow cells to 
lose epithelial cell-cell junction, reorganization of actin cytoskeleton, 
loss of epithelial proteins that promote cell-cell contact such as E-
cadherin, β- and γ-catenin, and zonula occludens-1 (ZO-1), and 
gain of mesenchymal markers such as vimentin, α-smooth muscle 
actin, N-cadherin, Snail and Slug.  
 
Loss of E-cadherin is considered the hallmark of EMT.  E-
cadherin is a membranous adhesion molecule and a calcium-
dependent glycoprotein, which is responsible for cell-cell contact 
and cell tight junctions in epithelial cells (Makrilia, Kollias, 
Manolopoulos, & Syrigos, 2009). E-cadherin cytoplasmic portion 
forms a complex with β-catenin. This complex stabilizes β-catenin 
on the plasma membrane and prevents β-catenin translocation to 
the cytosol. Cytosolic β-catenin is ubiquitinated by the degradation 
complex that consists of serine/threonine kinases CK1, glycogen 
synthase kinase-3β (GSK-3β), the adenomatous polyposis coli 
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protein (APC), and the scaffold protein axin, or β-catenin is 
translocated to the nucleus when the canonical  Wnt pathway is 
active (Schmalhofer, Brabletz, & Brabletz, 2009). Nuclear β-catenin 
binds with transcriptional complex T-cell factor (TCF)/lymphoid 
enhancer factor (LEF) which targets many oncogenes (Q. Wang, 
Sun, Allgayer, & Yang, 2010). This illustrate the importance of E-
cadherin role for maintaining cell phenotype and normal behavior. 
Many external inhibitors of E-cadherin and initiators EMT were 
identified such as transforming growth factor-β (TGF-β), fibronectin, 
epidermal growth factor (EGF) and platelet-derived growth factor 
(PDGF) (Camara & Jarai, 2010; M. Y. Lee, Chou, Tang, & Shen, 
2008; Sabbah et al., 2008). These external molecules initiates 
many signal transduction pathways such as Phosphoinositide 3-
kinases (PI3K)/ AKT, Mitogen-activated protein kinases (MAPK)/ 
Extracellular Receptor Kinase (ERK) and Smads (Camara & Jarai, 
2010; Sabbah et al., 2008). Activations of these signal pathways 
increase transcriptional inhibitors of E-cadherin such as zing finger 
binding transcriptional factors, namely Snail and Slug or as basic 
helix-loop-helix transcriptional factors, namely twist, Zinc finger E-
box-binding homeobox (ZEB) -1 and -2 (von Burstin et al., 2009; 
Voulgari & Pintzas, 2009). These transcriptional factors inhibit E-
cadherin through binding to the E-cadherin promoter site (E-box).   
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3.3.2 EMT in drug resistance and metastasis 
Several recent studies have demonstrated that EMT is 
associated with drug resistance and metastasis (Cheng et al., 
2007; Christiansen & Rajasekaran, 2006; DiMeo et al., 2009; Fuchs 
et al., 2008; Kudo-Saito, Shirako, Takeuchi, & Kawakami, 2009; 
Sarkar, Li, Wang, & Kong, 2009; Tsuji, Ibaragi, & Hu, 2009; 
Voulgari & Pintzas, 2009). Also, many emerging evidences have 
indicated EMT role in tumor progression (Thiery, 2002). EMT 
acquires cancer cells with mesenchymal phenotype which is 
characterized by loose embedding and loss of polarity (Kalluri & 
Weinberg, 2009). This phenotype gives cancer cells infiltrating and 
metastasis potential. Recently, Mendez et al found that metastatic 
cells express the mesenchymal marker, vimentin, and demonstrate 
spindle-shape morphology and more motility ability (Mendez, 
Kojima, & Goldman). Moreover, Arumugam et al showed that 
pancreatic cell lines that showed low expression of E-cadherin and 
high expression of mesenchymal marker, ZEB1, demonstrated high 
resistance to three conventional drugs used in pancreatic cancer 
treatment, gemcitabine, 5-FU, and cisplatin (Arumugam et al., 
2009). Furthermore, Yin et al showed that Snail overexpression in 
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pancreatic cancer cells enhanced metastasis and chemoresistance 
(Yin et al., 2007).  
 
Here in this study, we propose cav-1 as a crucial modulator 
of EMT and cell differentiation. We detected cav-1 at  pretranslation 
and translational levels in eight pancreatic cell lines. We chose the 
least cav-1 expressing –Panc 10.05- (Panc10/cav-1) cell line to 
infect it with cav-1 expressing vector. Consequently, cancer cells 
acquired different morphological phenotype and more cell adherens 
than control cells. After that, levels of E-cadherin and β-catenin 
were higher and localized in cell membrane. This was combined 
with diminishing of the E-cadherin inhibitor, Snail. Also, molecules 
such ERK, Smad2 were dephosphorylated and AKT was 
downregulated in cav-1 expressing cells. Prior cellular and 
molecular alternations decreased cancer cells migration and 
invasion potential, plus sensitized cancer cells toward doxorubicin. 
Also, we grown cells overexpressing cav-1 in three-dimensional 
culture to investigate cell polarity and behavior. Also, we studied 
the cell cycle of a metastatic cell line incubated with cav-1 peptide. 
Furthermore, in vivo study in nude mice showed that cav-1 
expressing tumors were less in weight and volume compared to 
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control tumors. Interestingly, cav-1 tumors contained nests of 
differentiated cells nests which were absent in control tumors. 
These differentiated cells exhibited strong E-cadherin and β-catenin 
signals in cell membrane while Snail was absent in cells cytoplasm 
or nucleus.  
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4. Material & Methods 
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4.1 Cell culture, stable retroviral transfection.  
Panc 10.05, Mia Paca, BxPC3, Aspc-1 and human 
pancreatic duct epithelial (HPDE) cell lines were purchased from 
American Type Culture Collection. HS766T and PK9 cell lines were 
a gift from Scott Kern (John Hopkins University), and HPAF II cell 
line was a gift from Surinder Batra (University of Nebraska Medical 
Center). All cell lines were maintained at 37 °C in 5% CO2 and 
grown in  RPMI 1640 (Gibco; Grand Island, NY, USA) supplemen-
ted with 10% fetal bovine serum (FBS) (Gibco), except Panc 10.05, 
where 10 I.U./ml of human recombinant insulin (Sigma-Aldrich Co.; 
St Louis, MO, USA) were added to the growing medium. Full-length 
cav-1 gene was subcloned in the pBabe retroviral vector using 
standard PCR (Capozza et al., 2005). Then, Phoenix, amphotropic 
packing cell line, was trasfected with pBabe vectors using a 
modified calcium phosphate method (Kinsella & Nolan, 1996). After 
transfection for 48 hours, viral supernatant was collected, filtered, 
and added to Panc 10.05 cells. Two cycles of infection were added 
every 12 hours. Puromycin (Sigma-Aldrich Co.) was added after the 
final infection cycle at a final concentration of 2.5μg.ml-1. Finally, the 
success of cav-1 infection was confirmed by Western blot analysis.  
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4.2 Real-time PCR analysis 
Cells were grown in 10 cm Petri dish (Corning Glass Works, 
Corning, NY) till 80% confluence. Then, culture medium was 
aspirated and cells were rinsed twice with PBS (Gibco). 1 ml of 
Trizol (Sigma-Aldrich Co.) was added to the plates and swirled. 
After that, Trizol suspension was transferred to tubes contain 200 μl 
chloroform (Sigma-Aldrich Co.). The tubes were vortexed, then 
centrifuged for 10 minutes at 13000 RPM. The clear upper zone, 
which has the RNA, was transferred to tubes contain 400 μl 
isopropanol (Sigma-Aldrich Co.) and vortexed. The mixture was left 
to settle for overnight at room temperature (RT). Next day, the 
tubes were centrifuged for 20 minutes at 13000 RPM, the 
supernatant was carefully aspirated and discard. Washing of RNA 
pellet was achieved by adding 100 μl of 75% Ethanol, and the 
mixture was centrifuged. Then the Ethanol was aspirated, and the 
pellet were left to dry for 30 minutes in RT. To dissolve the pellet, 
we added 100 μl of DEPC-treated water (Ambion; Austin, TX, USA) 
and left to dissolve for 30 minutes at 65°C. RNA quality and 
quantity was determined by using The NanoDrop ND-1000A 
Spectrophotometer (Ambion). Then, cDNA was synthesized from 
the purified mRNA using SuperScript III First-Strand (Invitrogen; 
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Carlsbad, CA, USA) according to the manufacture’s  instruction. 
Cav-1 and glyceraldehyde-3 phosphate dehydrogenase (GAPDH) 
probes were purchased as “assays on demand” (Applied 
Biosystems; Foster City, CA, USA) and GAPDH was used as 
housekeeping gene. cDNA was prepared, and subjected to real-
time PCR using the TaqMan technology (7500 Sequence Detector; 
Applied Biosystems). Detection was carried out in duplicates.  
 
4.3 Immunoblotting assays 
 Cells were lysed using RIPA buffer (50 mM Tris, pH 7.5, 
150 mM NaCl, 0.5% Sodium Deoxycholate, 1.0% Triton X-100, 
0.1% SDS), plus protease inhibitors (Roche Diagnostics; 
Indianapolis, IN, USA) and phosphatase inhibitors (Sigma-Aldrich 
Co.). Cell lysates were centrifuged to remove cell debris. Protein 
quantification was achieved by using BSA reagent (Pierce; 
Rockford, IL, USA) and the desired volume, which contains 50 μg 
protein, was determined. Cell lysate proteins were separated by 10-
12% SDS-PAGE electrophoresis then transferred overnight at 4°C 
to nitrocellulose membrane (Whatman; Dassel, Germany). The 
antibodies used for immunoblotting were the rabbit polyclonal anti-
caveolin-1 (N-20), and the mouse monoclonal anti-GAPDH were 
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purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), 
the mouse monoclonal anti-E-cadherin, the mouse monoclonal anti-
β-catenin, and the mouse monoclonal anti-Akt were purchased 
from BD Biosciences (San Jose, CA, USA), the rabbit polyclonal 
anti-Snail, the rabbit polyclonal anti-Smad2, the rabbit polyclonal 
phospho-Smad2 (465/7), the rabbit polyclonal anti-Erk1/2, the 
rabbit polyclonal anti-phospho-Erk1/2 (202/4), and the rabbit 
polyclonal anti-phospho-Akt (Ser473) were purchased from Cell 
Signaling Technologies (Danvers, MA, USA). Some of the later 
antibodies were used for immunofluorescence and 
immunohistochemistry.  
 
4.4 Immunofluorescence assay and confocal 
microscopy 
Panc10/cav-1 cells were plated on cover slips in 12-well 
plates and cultured for two days. Then cells were rinsed with 0.1 
mM CaCl2 and 1mM MgCl2 in PBS (PBS/CM), then fixed with 2% 
paraformaldehyde in PBS/CM for 30 minutes. After, cells were 
washed three times with PBS/CM , and then permeabilized with 
0.1% Triton-X100 and 0.2% bovine albumin serum in PBS/CM (IF 
buffer). After cells were quenched with 50 mM NH4Cl in PBS/CM for 
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10 minutes, cells were rinsed with IF buffer. Cells were incubated 
with (1:500) and E-cadherin (Mouse) (1:200), or β-catenin (Mouse) 
(1:200) antibodies for 1 hour at room temperature. Then cells were 
washed with IF buffer and  incubated with secondary antibody, 
Alexa Fluor goat anti-mouse 488 IgG (Molecular Probes; Eugene, 
OR, USA) for 30 minutes. After washing cells with IF buffer, cells 
were rinsed with PBS alone. Nuclei were stained with Hoechst 
33342 for 2 minutes, then cells were rinsed with PBS. Coverslips 
were mounted with ProLong Gold anti-fade (Molecular Probes) and 
left overnight in the dark. Images were acquired with a Zeiss 
LSM510 Meta confocal microscope system and analyzed with 
Zeiss LSM Browser (3,5,0,359; Zeiss). 
 
4.5 Akt activity 
Akt kinase activity was measured using nonradioactive AKT 
Kinase Assay kit (Cell Signaling Technologies). According to the 
manufacture’s instruction, stable infected Panc 10.05 cell lysates 
were incubated with immobilized Akt antibody beads for overnight 
at 4°C. Next day, the solution was centrifuged and the pellet was 
washed twice. Then, the pellet was suspended and incubated with 
the glycogen synthase kinase-3 α/β (GSK-3α/β) fusion protein for 
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30 minutes at 30 °C. After the reaction was stopped with 20 μl of 3X 
SDS, the samples were transferred to be immuneblotted with 
phospho-GSK-3 α/β (Ser21/9) antibody (Cell Signaling 
Technologies). 
 
4.6 Migration and invasion assays  
Cells invasion potential in vitro was measured using modified 
Boyden chamber assay (Albini et al., 1987; Hulit et al., 2007). 
Briefly, 2.5 x 104 Panc10/cav-1 and Panc10/pBabe cells were 
suspended in 0.5 ml of serum-free RPMI-1640, then added to 8 
μm-pore upper chamber (BD Biosciences). The upper chambers 
were either coated with Matrigel, for invasion assay, or not coated, 
for migration assays. The lower chambers contained RPMI-1640 
medium supplemented with 10% FBS served as a chemoattractant.  
After that, cells were incubated at 37 °C for 10 hours or 20 hours to 
migrate or invade, respectively. The non-invasive cells on the top of 
the upper chamber were removed using a cotton swap, then the 
invasive cells were stained with 0.5% crystal violet dissolved in 
methanol for 30-60 minutes. Chambers were rinsed with water, 
dried, and then examined under bright-field microscope. Invasion 
and migration values were obtained through counting 5 fields of 
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each chamber. The assay were carried out in triplicates in different 
time points.  
 
4.7 Drug sensitivity assay.  
Panc10/cav-1 were plated in 96-well dish. After 24 hours, 
cells medium was discarded, then a serial dilution of doxorubicin 
hydrochloride (Sigma-Aldrich Co.) were added to the cells for 48 
hours incubation. Cells survival was detected using CellTiter 96 
non-Radioactive Cell proliferation Assay kit (Promega; Madison, 
WI, USA). Survived cells formed a color solution which was 
detected at 570nm wavelength according to the manufacture’s 
instruction using an ELISA reader (Sun-
rise Remote, TECAN; Austria) .  Each concentration was performed 
in triplicates.  
 
4.8 Three Dimensional Cultures 
Matrigel of basement membranes extract of reduced growth 
factors (Cultrex; Gaithersburg, MD, USA) was defrosted and 100 μl 
of the Matrigel was transferred to cooled chamber slides (BD 
Falcon; Bedford, MA, USA). Then matrigel was evenly spreaded 
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with a 20 μl cooled tip. Slides were incubated in 37 °C for maximum 
of 3 hours to solidify. Cells were washed with cooled PBS twice, 
then they were trypsinized. Then cell suspension was collected with 
growth media and spinned for 4 minutes at 1000 RPM. Then the 
cells pellet was resuspended until the pellet was dispersed to single 
cell suspension. Cells were counted and then they were diluted to a 
final concentration 5000 cells/ml. The same volume of the cell 
suspension was mixed with equal volume of growth medium 
containing 4% of matrigel reduced growth factors plus 10 ng/ml of 
EGF (BD Bioscience) to reach a final cell suspension of 10000 cells 
with a 2% Matrigel plus 5 ng/ml EGF. The later suspension was 
transferred to chamber slide well that contains the solidified 
matrigel. Slides were incubated at 37 °C in 5% CO2 for 3 days. 
Images were acquired by an Axiovert 200 M 
microscope (Carl Zeiss; Oberkochen, Germany). This experiment 
was carried out in quadruplicates. 
 
4.9 Caveolin-1 peptide and cell cycle  
The scaffolding domain of Caveolin-1 was coupled with a 16-
amino acid peptide which is corresponding to the homeodomain of 
the Drosophila transcription factor antennapedia (AP), which 
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facilitate the uptake of AP-caveolin-1 (AP-cav-1) into mammalian 
cells through a nonendocytosis and nondegrative pathway (Derossi 
et al., 1996; Gratton et al., 2003). Biotinylated peptides 
corresponding to AP [(biotin)-RQPKIWFPNRRKPWKK-(OH)] and 
AP-cav-1[(biotin)-RQPKIWFPNRRKPWKK–
DGIWKASFTTFTVTKYWFYR-(OH)] were synthesized (at the Tufts 
University Core Facility). 5mM of the peptide, dissolved in the 
growth media, was incubated with Aspc-1 cell line in 37 °C for 48 
hours. Cells were washed by PBS, then trypsinized. Trypsinized 
cells were collected then spinned for 8 minutes at 1200 RPM. 
Supernatant was discarded and the pellet was washed by cold PBS 
twice.  Then, cells were dispersed in 70% ethanol to fix the cells 
overnight on the shaker at 4 °C. Next day, cell suspension was 
spinned, and ethanol supernatant was discarded. Cell pellet was 
washed with cold PBS once, then spinned. Cell pellet was 
suspended in 500 μl with the staining solution containing 0.05mg/ml 
propidum iodide (Invitrogen) plus 5 μg of RNAse A (Roche Applied 
Science; Indianapolis, IN, USA) for 30 minutes in 37 °C water bath 
in dark. Then, cell suspension was transferred to cell sorting tube. 
Cell cycle was determined by flow cytometry (Coulter Epics XL 
MCL software; Coulter Epics XL MCL System II 3.0; Beckman 
Coulter, Miami, FL).  
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4.10 Animal study 
All nude mice in this study were conducted according to the 
guidelines of the National Institutes of Health and the Thomas 
Jefferson University Institute for Animal Studies. Male nude mice at 
the age of 8 weeks were obtained from NIH. The mice were divided 
to two groups, each group had nine mice, then every mouse was 
injected in the left flank with 1 x 106 cells. After 7 weeks tumors 
appeared, extracted, then weighted and measured. Finally, tumors 
were embedded in paraffin blocks for further immunohistochemistry 
analysis.  
 
4.11 Immunohistochemistry 
Tumor slides were processed as we described before 
(Bonuccelli et al., 2009). Briefly, tumors embedded in paraffin were 
cut in 5 μm sections. Then, sections were deparaffinized with 
xylene and rehydrated with graded concentration of ethanol. 
Antigen retrival was performed in 100 mm/L sodium citrate buffer 
pH 6.0 for 10 minutes using an electric pressure cooker. Then 
sections were incubated with 3% H2O2 for 10 minutes, then sections 
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were washed and blocked with 10% goat serum in PBS for 1 hour 
at room temperature (RT). After that, slides were washed and 
incubated with primary antibodies anti-E-cadherin (1:400) or anti-β-
catenin (1:200) or anti-Snail (1:250) in blocking solution for 
overnight at 4 °C followed by incubation with biotinylated secondary 
antibody for 30 minutes at RT. Then, slides were washed in PBS 
and incubated with avidin/biotin-horesradish peroxidase reagent for 
30 minutes at RT. Next, slides were washed again and incubated 
with the 3,3-diaminobenzidine reagent until developing a brown 
color. Finally, slides were washed, then counterstained with 
hematoxylin, dehydrated, then mounted with coverslips.  
 
4.12 Statistical analysis 
Statistical significance was examined by Student’s t-test. 
Values of P < 0.05 were considered significant or lower were highly 
statistically significant. Values were expressed as means ± SE 
(Standard Error). 
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5. Results  
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5.1 Differential expression of caveolin-1 
To determine the lowest expressing pancreatic cell line to 
cav-1, we performed mRNA relative quantification and Western blot 
studies (Figure.8A and 8B). Immunoblotting study demonstrated 
that Panc 10.05 cell line has the lowest amount of cav-1 
(Figure.8B). So, we used Panc 10.05 cell to establish a stable 
infection of cav-1 expressing Panc 10.05 (Panc10/cav-1) 
(Figure.8C).  
 
5.2 Cells expressing cav-1 acquire polygonal 
morphology, have more cell-cell contact and 
express E-cadherin and β-catenin in the plasma 
membrane  
Subsequently to the cav-1 infection, Panc10/cav-1 exhibited 
different morphology than Panc 10.05 cells infected with empty 
vector (Panc10/pBabe). Panc10/cav-1 exhibited more cell-cell 
contacts and polygonal shape, in the contrary Panc10/pBabe cells 
were growing solely and exhibiting a fibroblastic spindle-shape 
(Figure.9A). This alteration of cell-cell behavior in Panc10/cav-1 
was accompanied with elevation of E-cadherin expression, which is 
shown in figure.9B. Furthermore, immunofluorescence analysis 
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displays membranous expression of E-cadherin in Panc10/cav-1 
cells (Figure.9C). Consequently to E-cadherin expression, β-
catenin expression was restored and was stabilized in the plasma 
membrane of Panc10/cav-1 cells (Figure.9B and 9C). 
 
5.3 Cav-1 suppresses EMT pathways 
To investigate the mechanism by which cav-1 influence in E-
cadherin restoration and suppression of EMT, we performed 
immunoblotting analysis against several critical molecules that are 
responsible for E-cadherin suppression. Interestingly we found that, 
ERK and Smad2 activity were lower (Figure.10A), and total AKT 
and Snail expressions were down-regulated in cav-1 expressing 
cells compared to control lysates (Figure.10B). Previous studies 
highlighted ERK and Smad role in EMT induction (Davies et al., 
2005). Additionally, AKT activity analysis demonstrates reduced 
phospho-GSK-3α/β level (Figure.10C), which was attributed to 
reduced AKT activity in cav-1 expressing cells. AKT  and its 
pathway has an immense influence in EMT induction (Grille et al., 
2003). Mainly this influence is through the expression of the 
transcriptional factor, Snail, which down-regulates E-cadherin to 
initiate EMT.  
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5.4 Cav-1 attenuates pancreatic cancer cell 
behavior such migration and invasion, and drug 
resistance  
AKT and ERK molecules play important role in cancer cells 
invasion and migration. To investigate if cav-1 effect over these two 
molecules can alters cells migration and invasion capacity, we 
seeded Panc10/cav-1 cells over 8 μm-pore Transwells, which were 
not coated or not coated with Matrigel for migration and invasion, 
respectively. As we expected, cav-1 expression dramatically 
decreased migration and invasion capacity approximately by 2.5 
and 16-folds, respectively, as compared to Panc10/pBabe capacity 
(Figure.11A). Han et al explained that cav-1 decreases invasion 
potential via inhibition of matrix metalloproteases (MMP)-2 and 
MMP-9 secretion and the reduced ERK activity is responsible for 
migration and invasion inhibition (F. Han & Zhu, 2009). Doxorubicin 
is a promising cytotoxic drug, especially when is combined with Akt 
inhibitors (Y. A. Wang, Johnson, Brown, & Dobson, 2009). As we 
have shown before that cav-1 inhibits AKT activity, so we have 
chosen doxorubicin to study cav-1 expressing cells 
chemosensitivity. A serial dilution of doxorubicin were added to 
Panc10/cav-1 cells. Panc10/cav-1 cells demonstrated significant 
sensitivity to doxorubicin than Panc10/pBabe cells did (Figure.11B). 
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We suggest that this sensitivity is due to inhibition of EMT initiators 
and pro-survival molecules such AKT and ERK by cav-1 
expression.  
 
5.5 Cav-1 inhibits cancer cells loss of polarity, acini 
irregularity and branching in three-dimensional 
culture 
As we mentioned before, that EMT is a biological process 
which potentiates tumor progression by the loss of polarity 
(Moreno-Bueno, Portillo, & Cano, 2008). Also, cav-1 was found to 
be an important regulator of cell polarity (Grande-Garcia & del 
Pozo, 2008; Grande-Garcia et al., 2007). So to determine the cav-1 
expression role in EMT and cell polarity, we used three-dimensional 
culture which is used for investigating of cell polarity behavior 
(Shaw, Wrobel, & Brugge, 2004). We overlaid cells over Matrigel 
reduced from growth factors, then cells were incubated with growth 
medium supplemented with 2% of Matrigel and stimulated with 5 
ng/ml EGF. After 3 days cav-1 deficient  (Panc10/pBabe) cells 
displayed branching (tubulogenesis) morphogenesis and more 
proliferation and irregularity (irregular outline, multilobular). Debnath 
et al described that branching in three-dimensional culture requires  
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EMT (Debnath & Brugge, 2005). While Panc10/cav-1 cells showed 
dramatic decrease of branching and irregular spheres, and 
significant increase of polarized regular spheres formation 
(Figure.12).  
 
5.6 Cav-1 peptide induces G0/G1 arrest  
Cav-1 scaffolding domain peptide coupled with 
antennapedia (AP-Cav-1) was found to be permeabilized into cell 
membrane and reduces inflammation, and tumor progression in 
mice (Bucci et al., 2000; Gratton et al., 2003). In this study we 
wanted to demonstrate the effect of AP-Cav-1 peptide on cancer 
cell cycle. Using flow cytometry, Aspc-1 cells that treated with AP-
Cav-1 showed significant induction of G0/G1 arrest and  significant 
reduction of S and G2/M Phases (Tabel.5).  
 
5.7 Cav-1 impairs tumorigenesis and shrinks tumor 
mass and volume 
Panc 10.05 cell line is tumorigenic, to evaluate if cav-1 can 
impair tumorigenesis potential of Panc 10.05 cell line after cav-1 
infection , we injected infected cells to mice flanks.  After 7 weeks, 
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tumors were extracted and weighed and volumes were measured 
as an ellipsoid which V = 
4
3
  X π X a X b2, where V is the tumor 
volume, a is the length of the long axis, and b is the length of the 
short axis. Surprisingly, Panc10/cav-1 tumor mass and volume 
were decreased roughly 9 and 4-folds, respectively, compared to 
Panc10/pBabe tumors (Figure.13A).  
 
5.8 Cav-1 expression restores cells differentiation 
Astonishingly after H&E staining, Panc10/cav-1 tumor 
displayed multiple nests of organized cells layers displaying semi 
differentiation towards squamous architecture (Figure.13B). These 
cells were surrounded by eosinophilic fibroblasts, giving a structure 
similar to epithelial cells surrounded by a basement membrane. 
However these nests were found in 7 out of 9 cav-1 expressing 
tumors, they were totally absent in control Panc10/pBabe tumors . 
These nests confirm that cav-1 plays a critical role in restoring cells 
differentiation and also these differentiated cells recruited 
fibroblasts from the environment to act as a basement membrane.  
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5.9 E-cadherin and β-catenin are expressed and 
Snail production is lost in cav-1 tumor cell nests 
To examine if the differentiated nests have different E-
cadherin and β-catenin expression level than the undifferentiated 
cells, we performed immunohistochemistry analysis. Indeedly, 
differentiated cells showed high membranous signal for E-cadherin 
and β-catenin (Figure.14). Moreover, Snail signal was absent from 
nest cells cytoplasm and nucleus compared to the surrounding 
undifferentiated cells. All of the in vivo results are consistent with in 
vitro results, which explicit the critical role of cav-1 in suppression of 
EMT in pancreatic cancer.  
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6. Discussion & Conclusion 
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In this study we wanted to evaluate caveolin-1 (cav-1) 
regulatory role in the E-cadherin expression and epithelial to 
mesenchymal transition –EMT- in pancreatic cancer. Pancreatic 
cancer is considered to be the fourth leading cause of death related 
to cancer due to its drug resistance and rapid metastasis (Sarkar, 
Li, Wang, & Kong, 2009). These features have been related to EMT 
(Sarkar, Li, Wang, & Kong, 2009). EMT is a biological and 
molecular process in which epithelial phenotype and cell polarity 
are lost and cells gain a fibroblastic spindle-shape morphology 
which allow cells to infiltrate tissues and invade organs (Thiery, 
2002). Interestingly, enforcing cav-1 expression in Panc 10.05 cells 
induced them to gain a different phenotype than control cells. Our 
cav-1 expressing cells displayed cell-cell adherens which were 
absent in the spindle-shape control cells. Then, we examined levels 
of E-cadherin as it is responsible for cell adherence and tight 
junction. Our immunoblotting and immunofluorescence analysis 
indicated that E-cadherin was absent in Panc10/pBabe but E-
cadherin expression was restored after Panc 10.05 were infected 
with cav-1. Panc10/cav-1 displayed E-cadherin localization in the 
cell membrane.  Restoration of E-cadherin expression is critical, as 
E-cadherin loss is correlated with undifferentiated and anaplastic 
pancreatic tumors leading to worse prognosis as compared to 
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differentiated pancreatic tumors that express E-cadherin (Winter et 
al., 2008). Moreover, recent studies implied that chemoresistant 
pancreatic cancer cells were deprived from E-cadherin, and to 
sensitize these cells to cytotoxic drugs, cells need to re-express E-
cadherin (Arumugam et al., 2009). Similarly to E-cadherin function, 
we previously reported that cav-1 stabilizes β-catenin in the 
caveolae of the cell membrane (Galbiati et al., 2000). Such 
stabilization prevents β-catenin to form a complex with T-cell factor 
(TCF) which translocates to the nucleus to initiate EMT and 
invasion (Reichert, Muller, & Hunziker, 2000). The formation of this 
complex is also promoted by Snail, that has a reciprocal correlation 
with E-cadherin expression (Stemmer, de Craene, Berx, & 
Behrens, 2008; Q. Wang, Sun, Allgayer, & Yang, 2010).  Snail 
suppresses E-cadherin expression through recruiting histone 
deacetylases (HDAC) binding to the E-boxes in the E-cadherin 
promoter (von Burstin et al., 2009). Also, Yin et al. showed that 
Snail overexpression in pancreatic cancer cells was correlated with 
lymph node invasion and distant metastasis (Yin et al., 2007). Also, 
they found that overexpressing Snail in Panc1 cells enhanced 
metastasis in orthotopic mice and promoted chemoresistance to 5-
fluorouracil or gemcitabine. Our results show that cav-1 down-
regulates Snail expression. To better understand how cav-1 affects 
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Snail expression, we investigated the three main molecules 
responsible for Snail activation, namely ERK, Smad2 and AKT, 
which are involved in phosphatidylinositol 3-kinase, mitogen-
activated protein kinase (MAPK),  TGF-β and (PI3K)/AKT 
pathways, respectively (Camara & Jarai, 2010; Grotegut, von 
Schweinitz, Christofori, & Lehembre, 2006; Larue & Bellacosa, 
2005; Peinado, Quintanilla, & Cano, 2003). Li et a.l demonstrated 
that E-cadherin re-expression in breast cancer cells was not 
enough for EMT reversion unless ERK was suppressed (Q. Li & 
Mattingly, 2008). Moreover, previous studies showed that MAPK 
regulates TGF-β role to act as a tumor promoter (Chow et al., 
2007). Also, TGF-β pathway activates by phosphorylation Smad2 to 
be translocated to the nucleus which bind with EMT transcriptional 
factors such ZEB1 or ZEB2 (K. A. Brown, Pietenpol, & Moses, 
2007). Remarkably, our results show that cav-1 down-regulates 
both ERK and Smad2 activity restoring epithelial cell status. 
Another critical pathway down-regulated by cav-1 is AKT. AKT  is 
not only an EMT inducer, but also it is a pro-survival and metastasis 
promoter molecule (Grille et al., 2003).  
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We also found that EMT features, such migration, invasion, 
and chemoresistance, were eventually altered. A previous study 
has demonstrated that cav-1, through ERK inhibition, suppresses 
migration and invasion in pancreatic cancer cells, which is 
confirmed in our study (F. Han, Gu, Chen, & Zhu, 2009). 
Importantly, cav-1 down-regulated AKT, which is a pro-survival 
molecule. Many previous studies indicated that AKT pathway in 
breast, lung, gastric, and uterine cancer is responsible for 
doxorubicin resistance (Gagnon, Van Themsche, Turner, Leblanc, 
& Asselin, 2008; Tari, Mehta, & Lopez-Berestein, 2001; Y. A. 
Wang, Johnson, Brown, & Dobson, 2009; Yu et al., 2008; Zhao et 
al., 2004). In this study, we also showed that cav-1 sensitize 
pancreatic cancer cell to doxorubicin through down-regulation of 
AKT pathway. Also, Arumugam et al. indicated that EMT induces 
chemoresistant toward gemcitabine and 5-flurouracil in pancreatic 
cancer cells (Arumugam et al., 2009), which is confirmed by our 
data that cav-1 inhibitions to EMT leads to cancer cell 
chemosensitization. 
 
Conventional two-dimensional cell culture has been found to 
distort outcomes by changing cells environment from three-
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dimensional environment to artificial flat rigid surfaces (Elsdale & 
Bard, 1972). On the contrary, three-dimensional cell culture system  
provides the most resembling environment for cells, where the cells 
sense the extracellular matrix and mediate various signals involving 
cell growth, migration, differentiation, survival  (Cukierman, Pankov, 
& Yamada, 2002). Branching or tubulogenesis of cells in three-
dimensional cultures requires EMT and activation of ERK pathway 
(Debnath & Brugge, 2005; Montesano, Matsumoto, Nakamura, & 
Orci, 1991; Soriano, Pepper, Nakamura, Orci, & Montesano, 1995). 
Here, we used three-dimensional culture to grow cav-1 expressing 
cells. Our data shows that Panc10/cav-1 cells displayed more 
significant regular spheres accompanied by less branching and 
irregularity of cell spheres after three days incubation with EGF. 
These results go along with Gutierrez-Barrera et al. results, where 
they showed that pancreatic cancer cell lines formed irregular 
spheres unlike the non cancerous human pancreatic ductal 
epithelial (HPDE) cell line (Gutierrez-Barrera, Menter, Abbruzzese, 
& Reddy, 2007). 
 
Our laboratory have previously reported that cav-1 
negatively regulates cell cycle and induces Inducing G0/G1 arrest 
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(Galbiati, Volonte et al., 2001). Here, we incubated cav-1 peptide  
containing the scaffolding domain of cav-1 with a metastatic cell 
line, Aspc-1 (Chen et al., 1982) for two days. Using flow cytometry, 
we found that Ap-CAv-1 also induced G0/G1 arrest and significantly 
reduces S and G2/M phases. This result was also demonstrated by 
Han et al. in Panc-1 cells expressing cav-1 (F. Han, Gu, Chen, & 
Zhu, 2009). 
 
Previous studies demonstrated cav-1 implication in growth 
tumor inhibition (F. Han, Gu, Chen, & Zhu, 2009; Zhang et al., 
2008). Also, here, our results displayed cav-1 tumors were smaller 
in weight and volume compared to the Panc10/pBabe control 
tumors. More interestingly, cav-1 tumors showed nests of 
differentiated cells, which were absent in control tumors. These 
differentiated cells expressed high levels of E-cadherin and β-
catenin in the plasma membrane and their expression were lost in 
poor differentiated cells. This remarkable finding suggests a critical 
role of cav-1in cell differentiation and epithelial cell plasticity.  
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Although our results describe cav-1 as a tumor suppressor in 
pancreatic cancer, clinical data portrays cav-1 as a tumor promoter 
and correlates it with tumor grade and poor prognosis (Witkiewicz 
et al., 2008). This different discrepancy is maybe due to the fact 
that cav-1 loses its tumor suppression role or gains an oncogenic 
function in higher tumor grades (Bonuccelli et al., 2009). Another 
possible explanation is that E-cadherin expression is a necessity for 
cav-1 to act as a tumor suppressor, as E-cadherin inhibits the β-
catenin-TCF oncogenic pathway (Torres et al., 2007). This relation 
of cav-1 and E-cadherin complex seems to be important to 
determine the behavior of cav-1 which effects the overall behavior 
of pancreatic cancer cells. 
 
In conclusion, our data demonstrate cav-1 as be a potential 
cure for pancreatic cancer. We showed that cav-1 retrieved 
epithelial status of pancreatic cells and maintained E-cadherin in 
plasma membrane and cell differentiation and polarity. These 
promising findings encourage us to expand our research to include 
other molecules and to study other possible mechanisms that will 
explain better cav-1 as a potential cure for pancreatic cancer.  
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7. Figures & Tables  
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Table.1: Genes associated with high risk of pancreatic cancer. 3 FDR, 3 or more first-degree relatives with 
pancreatic cancer; FAMMM, familial atypical multiple mole melanoma syndrome; HNPCC, hereditary 
nonpolyposis colorectal cancer syndrome; NS, nonspecific. Adopted with modification from Maitra et al (Maitra & 
Hruban, 2008).  
Individual Gene Relative Risk Risk by 70 Cancer 
Morphology 
Other Cancers 
No history None 1 0.5% NS None 
Breast Cancer BRCA2 3.5-10X 5% NS Breast, ovary, and 
prostate 
BRCA1 2X 1% Breast cancer with 
basaloid features 
Breast, ovary, and 
prostate 
FAMMM P16 (CDKN2A) 20-34X 10%-17% NS Melanoma 
Familial pancreatic 
cancer (3 FDR) 
Unknown 32X 16% NS Unknown 
Peutz-Jeghers STK11/LKB1 132X 30%-60% NS Gastroesophageal, 
small bowel, 
colorectal, and breast 
HNPCC hMHL1, hMSH2, 
others 
Unknown < 5% Medullary and colloid 
phenotypes 
Colorectal, 
endometrial, stomach, 
ovarian, ureter and 
renal pelvis, biliary 
tract, and brain 
Young-age-onset 
pancreatic cancer 
FANC-C and FANC-G Unknown Unknown NS Unknown 
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Figure.1:  Examples of each grade of PanIN. In PanIN/L1A (A), the 
columnar cells have abundant apical cytoplasmic mucin but there 
are no papillae, the nuclei are basally located, and there is no 
cytologic atypia. In PanIN1B (B), similar cells line well-formed 
papillae. Ducts involved by PanIN2 (C) demonstrate full-thickness 
pseudostratification of nuclei with mild-to-moderate cytologic 
abnormalities. In PanIN3 (D), there is complete loss of polarity, 
budding of cellular tufts into the duct lumen, and significant nuclear 
atypia. Adopted from Hruban et al (R. H. Hruban et al., 2004).  
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Figure.2: Pancreatic cancer progression. The upper blue part 
shows the progression of normal epithelial duct until the duct cells 
transform to pancreatic ductal adenocarcinoma –PDA- cells. The 
lower part shows the genetic modifications in pancreatic cancer 
progression, where it starts with telomeres shorting to prone the 
DNA to genetical mutations then activation mutation of KRAS in the 
first stages of cancer progression. Then several losses of tumor 
suppressor genes at the middle and late stages of cancer 
progression. The figure adopted with changes from Hruban et al (R. 
H. Hruban, Wilentz, & Kern, 2000). 
 
Normal Duct PanIN-1 A PanIN-1 B PanIN-2 PanIN-3 PDA 
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        Wild-type        Cav-2 KO 
Skeletal Muscle 
 
 
 
 
 Wild-type   Cav-3 KO 
Figure.3: Caveolae formation: cav-1 and cav-3 are required, but 
not cav-2 is required, for caveolae formation. Caveolae appear as 
50- to 100 nm plasmalemmal invaginations (see arrows) by 
transmission electron microscopy. They are particularly abundant in 
mouse embryonic fibroblasts (MEFs), endothelial cells and skeletal 
muscle fibers. Note that in MEFs isolated from cav-1 null (-/-) mice 
(upper panel), the caveolae organelles are completely absent 
(Razani et al., 2001) and are also lacking in most other cells and 
tissues. Conversely, cav-2 is not required for caveolae formation  
since cav-2 null (-/-) mice do not display any perturbations of 
caveolae biogenesis (middle panel) (Razani, Wang et al., 2002). 
Cav-3 null (-/-) mice showed only defectiveness in striated muscle 
cell, such as skeletal muscle fibers (lowest panel) (Galbiati, Razani, 
& Lisanti, 2001b). Compiled from micrographs in (Galbiati, Razani, 
& Lisanti, 2001b; Razani et al., 2001; Razani, Wang et al., 2002) 
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Figure.4: Phylogenic analysis of the caveolin gene family. 
Predicted evolutionary grouping for all caveolin family sequences. 
Adopted with change from Williams T et al (Williams & Lisanti, 
2004). 
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Figure.5: Predicted membrane topology of cav-1. Cav-1 monomer 
forms dimmers. However, ~14-16 monomers normally self-
associate to form a single caveolin homo-oligomer (the caveolar 
assembly unit, akin to the clathrin triskelion). Both N- and C-
terminal domains are oriented towards the Cytosolic face of the 
plasma membrane, with a hair-pin loop structure inserted with the 
membrane bilayers. The figure adopted from William et al (Williams 
& Lisanti, 2004). 
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Figure.6: Protein sequence alignment of the human caveolin gene 
family. The red box indicates the “caveolin signature motif”. The 
oligomerization domain (Cav-1, residues 61-101), the scaffolding 
domain (Cav-1, residues 82-101), and the transmembrane region 
(Cav-1, residues 102-134) are all shown. Violet circules indicate 
translation initiation sites (methionine). The internal start site at 
position 32 in cav-1 indicates the start of the β-isoform of cav-1. 
Identical residues are high-lighten in rose. This figure is adopted 
with modification from Razani et al (Razani, Wang et al., 2002). 
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Gene Species Genbank 
Accession No. 
Cav-1 Human 
Bovine 
Dog 
Chicken 
Mouse 
Rat 
Xenopus 
Fugu 
C. elegans 
Z18951 
U86639 
U47060 
L01582 
U07645 
AF439778 
AF455042 
AJ010316 
U66405 
Cav-2 Human 
Dog 
Mouse 
Rat 
Xenopus 
Fugu 
C. elegans 
AF035752 
AF039223 
AF141322 
AF439780 
AF455043 
AJ010316 
U75587 
Cav-3 Human 
Mouse 
Rat 
Xenopus 
AF043101 
U36579 
U31968 
AF455044 
 
Tabel.2: List of cloned caveolin cDNAs.
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Table.3: Overview of human caveolin genomic organization and protein product. Pb=base pair, kb=kilobases, 
AA= amino acids. 
Human 
Gene 
Human 
Chromosomal 
Location 
Exon Size 
(bp) 
Intron Size 
(Kb) 
Protein 
Residues 
Encoded 
Length 
(AA) 
% of 
similarity 
(identity) 
to 
Human 
Cav-1 
% of 
similarity 
(identity) 
to 
Human 
Cav-2 
Expression 
patterns 
Cav-1 7q31.1 1 
2 
3 
30 
165 
342 
1 
2 
1.47 
31.8 
1-10 
11-65 
66-178 
178 100 59 (40) Ubiquitous; 
highest levels in 
adipocytes, 
endothelia, 
smooth muscle 
cells, and Type I 
pneumocytes 
Cav-2 7q31.1 1 
2a 
2b 
150 
188 
151 
1 
2 
0.33 
5.76 
1-50 
51-112 
113-162 
162 58 (38) 100 Co-expressed 
with Cav-1 
Cav-3 3q25 1 
2 
114 
342 
1 ? 1-38 
39-151 
151 85 (65) 60 (39) Muscle-specific; 
primarily in 
skeletal and 
cardiac 
myocytes 
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Oncogene References 
c-Myc (Park et al., 2001; Timme et al., 
2000) 
N-Myc (Park et al., 2001) 
bcr-abl (Koleske, Baltimore, & Lisanti, 
1995) 
v-Abl (Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999; 
Koleske, Baltimore, & Lisanti, 
1995) 
H-RasG12V (Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999; 
Koleske, Baltimore, & Lisanti, 
1995) 
H-RasQ61L (Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999) 
N-RasQ61K (Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999) 
K-RasG12V (Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999) 
c-Src or v-Src (Engelman, Lee et al., 1998; 
Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999) 
c-Neu/ErbB2 (Engelman, Lee et al., 1998) 
crk1 (Koleske, Baltimore, & Lisanti, 
1995) 
HPV E6 (Razani et al., 2000) 
PyMT Ag (Koleske, Baltimore, & Lisanti, 
1995) 
v-Raf (Engelman, Zhang, Razani, 
Pestell, & Lisanti, 1999) 
PDK1 (Xie, Zeng, Waldman, & Glazer, 
2003) 
 
Tabel.4: Cellular oncoproteins that down-regulate Cav-1 
expression. 
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Figure.7: Epithelial-mesenchymal transition. Arranged 
epithelial cells show cells adherens, tight junction and 
desmosomes (Red junctions). Through epithelial-
mesenchymal transition, epithelial cells transforms to 
mesenchymal phenotype, which is characterized by loss of 
orientation and high migration and invasion potential. 
Adopted with modification from Kalluri et al (Kalluri & 
Weinberg, 2009). 
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Figure.8: Caveolin-1 expression level in eight human 
pancreatic cell lines. A, eight pancreatic cell lines mRNA 
were extracted by Trizol. Using Real-time PCR, cav-1 mRNA 
was quantified and normalized with GAPDH. B, aliquots of 
the eight pancreatic cell lines containing 50 μg of total protein 
were separated with 12% SDS-PAGE then transferred to 
nitrocellulose membranes and immuneblotted with anti-cav-1 
(N-20) against α isoform of caveolin-1 and reprobed with anti-
GAPDH to confirm equal loading. C, successful infection of 
Panc 10.05 with pBabe (Empty vector) or with pBabe/cav-1. 
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Figure.9: Cav-1 alters cells morphology and restores E-cadherin and β-catenin expression. A, 
Panc10/pBabe cells displays single spindle shape elongated cell, while Panc10/cav-1  show polygonal 
morphology and more cell-cell contact (10X). Black box, 8X zoom, bar, 20 μm. B, cav-1 expression 
restores E-cadherin and β-catenin. C, immunofluorescence analysis shows that, membranous E-
cadherin and β-catenin signals were detected in Panc10/cav-1 cells, whereas these signals were lost 
in Panc10/pBabe cells. Bar, 20 μm. 
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Figure.10: EMT pathways are downregulated by caveolin-1 
expression. A,. phosphorylation levels of ERK and Smad2 were 
downregulated. B, total AKT, phospho-AKT and Snail expression 
were decreased in cav-1 expressing cells. C, AKT activity was 
downregulated in Panc10/cav-1. Fusion protein GSK-3α/β was 
used as a substrate for phospho-AKT. Note that AKT activity in cav-
1 expressing cells is decreased compared to Panc10/pBabe. 
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Figure.11: Cav-1 attenuates pancreatic cancer cells migration, 
invasion and drug resistance. A, migration and invasion are 
suppressed in cav-1 expressing cells. Column, average of cell 
number counted per field of three independent experiments, bar, 
SE. B, cav-1 sensitizes pancreatic cancer cells to doxorubicin. 
Each concentration was carried out in triplicates. Bar, SE. *, P < 
0.05. §, P < 0.01, ***. P < 0.0005.  
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Figure.12: Cav-1 increases regularity of formed acini in three-dimensional Matrigel cultures. A, Cells were 
overlaid on 100% Matrigel basement membranes extract of reduced growth and incubated with complete growth 
medium and supplemented with 2% Matrigel and stimulated with 5 ng/ml EGF. Images acquisition was 
performed after 3 days of incubation. Panc10/cav-1 cells show small regular (smooth and spherical shape) acini, 
where Panc10/pBabe cells displayed branching (tubulogenesis) (Arrow) and more irregularity (irregular outline, 
multilobular) (O). Bar, 60 μm. B, Panc10/cav-1 cells showed more regular acini than Panc10/pBabe which  were 
more irregular and branching acini. Column, every experiment was performed in quadruplicates, bar, SE. *, P < 
0.05. ***, P < 0.0005.    
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Cell Line G0/G1% S% G2/M% Apoptosis% 
Aspc1+AP 58.525±1.96* 21.275±0.55* 18.475±0.64* 0.805±0.14 
Aspc1+ 
5mM AP-
Cav-1 
62.225±1.17 19.775±0.97 16.775±0.7 0.945±0.19 
 
Tabel.5: Cave-1 down-regulate cell cycle. Flow cytometry analysis 
of Aspc-1 cells incubated with AP and AP-Cav-1 peptides to 
determine cell cycle and apoptosis. Data represent the mean ± SD 
of 4 independent experiments. *, P < 0.05.  
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Figure.13: Cav-1 reduces tumor size and recovers tumors cells 
differentiation. A, the two histograms represent that cav-1 
expression decreases tumors weight and volume. Column, mean of 
weight or volume of nine tumors for each cell line. bar, SE. *, P < 
0.01. **, P < 0.005. B, cav-1 restores cancer cells differentiation. 
H&E staining shows islets of differentiated cells (Asterisk) only in 
Panc10/cav-1 tumors. Note that eosinophilic fibroblasts surrounds 
the differentiated cells. 
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Figure.14: Cav-1 expression restores membranous E-cadherin in 
tumor differentiated islets. Differentiated cells in Panc10/cav-1 
tumors express membranous E-cadherin and β-catenin as 
compared to Panc10/pBabe tumors. Note Snail expression in poor 
differentiated cells cytoplasm and nucleus, while Snail expression is 
suppressed in differentiated cells (40X). 
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